0001144204-16-082221.txt : 20160216 0001144204-16-082221.hdr.sgml : 20160215 20160216120110 ACCESSION NUMBER: 0001144204-16-082221 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 34 CONFORMED PERIOD OF REPORT: 20151231 FILED AS OF DATE: 20160216 DATE AS OF CHANGE: 20160216 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ALLIED HEALTHCARE PRODUCTS INC CENTRAL INDEX KEY: 0000874710 STANDARD INDUSTRIAL CLASSIFICATION: ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842] IRS NUMBER: 231370721 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-19266 FILM NUMBER: 161425147 BUSINESS ADDRESS: STREET 1: 1720 SUBLETTE AVE CITY: ST LOUIS STATE: MO ZIP: 63110 BUSINESS PHONE: 3147712400 MAIL ADDRESS: STREET 1: 1720 SUBLETTE AVENUE CITY: ST LOUIS STATE: MO ZIP: 63110 10-Q 1 v430780_10q.htm FORM 10-Q

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 10-Q

xQuarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

For the quarterly period ended December 31, 2015

 

¨Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

For the transition period from________ to ________

 

Commission File Number: 0-19266

 

ALLIED HEALTHCARE PRODUCTS, INC.

(Exact name of registrant as specified in its charter)

Delaware   25-1370721
(State or other jurisdiction of   (I.R.S. Employer
Incorporation or organization)   Identification No.)

 

1720 Sublette Avenue, St. Louis, Missouri 63110

(Address of principal executive offices, including zip code)

 

(314) 771-2400

(Registrant’s telephone number, including area code)

 

N/A

(Former name, former address and former fiscal year, if changed since last report)

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding twelve months (or for such shorter periods that the registrant was required to file such reports, and (2) has been subject to such filing requirements for the past ninety days. Yes x No ¨

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No ¨

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of "large accelerated filer,” “accelerated filer" and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer  ¨   Accelerated filer ¨
     
Non-accelerated filer ¨ (Do not check if smaller reporting company) Smaller reporting company x

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes ¨ No x     

 

The number of shares of common stock outstanding at January 30, 2016 is 8,027,147 shares.

 

   

 

 

INDEX

 

  Page
Number
Part I – Financial Information  
  Item 1. Financial Statements
    Statement of Operations -  Three and six months ended December 31, 2015 and 2014 (Unaudited) 3
       
    Balance Sheet - December 31, 2015 (Unaudited) and June 30, 2015 4 - 5
       
    Statement of Cash Flows - Six months ended December 31, 2015 and 2014 (Unaudited) 6
       
    Notes to Financial Statements (Unaudited) 7 – 13
       
  Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 13 – 17
       
  Item 3. Quantitative and Qualitative Disclosure about Market Risk 17
       
  Item 4. Controls and Procedures 18
       
Part II - Other Information
       
  Item 1. Legal Proceedings 18-19
       
  Item 6. Exhibits 19-20
       
    Signature 20

 

SAFE HARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

 

Statements contained in this Report, which are not historical facts or information, are "forward-looking statements." Words such as "believe," "expect," "intend," "will," "should," and other expressions that indicate future events and trends identify such forward-looking statements. These forward-looking statements involve risks and uncertainties, which could cause the outcome and future results of operations, and financial condition to be materially different than stated or anticipated based on the forward-looking statements. Such risks and uncertainties include both general economic risks and uncertainties, risks and uncertainties affecting the demand for and economic factors affecting the delivery of health care services, both in the United States and in our overseas markets, impacts of the U.S. Affordable Care Act, the outcome of litigation proceedings and specific matters which relate directly to the Company's operations and properties as discussed in the Company’s annual report on Form 10-K for the year ended June 30, 2015. The Company cautions that any forward-looking statements contained in this report reflect only the belief of the Company or its management at the time the statement was made. Although the Company believes such forward-looking statements are based upon reasonable assumptions, such assumptions may ultimately prove inaccurate or incomplete. The Company undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date on which the statement was made.

 

 2 

 

 

PART I.     FINANCIAL INFORMATION

 

Item 1.     Financial Statements

 

ALLIED HEALTHCARE PRODUCTS, INC.

STATEMENT OF OPERATIONS

(UNAUDITED)

 

   Three months ended   Six months ended 
   December 31,   December 31, 
   2015   2014   2015   2014 
                 
Net sales  $8,846,359   $8,999,662   $17,309,196   $17,844,929 
Cost of sales   7,067,748    6,841,177    13,832,294    14,111,661 
Gross profit   1,778,611    2,158,485    3,476,902    3,733,268 
                     
Selling, general and                    
administrative expenses   2,466,359    2,193,501    4,799,371    4,465,789 
Loss from operations   (687,748)   (35,016)   (1,322,469)   (732,521)
                     
Other (income) expenses:                    
Interest income   (838)   (799)   (1,902)   (1,554)
Other, net   21,854    10,533    41,662    21,958 
    21,016    9,734    39,760    20,404 
                     
Loss before benefit from income taxes   (708,764)   (44,750)   (1,362,229)   (752,925)
Benefit from income taxes   -    -    (123,907)   - 
Net loss  $(708,764)  $(44,750)  $(1,238,322)  $(752,925)
                     
Basic loss per share  $(0.09)  $(0.01)  $(0.15)  $(0.09)
                     
Diluted loss per share  $(0.09)  $(0.01)  $(0.15)  $(0.09)
                     
Weighted average shares  outstanding - basic   8,027,147    8,027,147    8,027,147    8,027,147 
                     
Weighted average shares  outstanding - diluted   8,027,147    8,027,147    8,027,147    8,027,147 

 

See accompanying Notes to Financial Statements.

 

 3 

 

 

ALLIED HEALTHCARE PRODUCTS, INC.

BALANCE SHEET

ASSETS

 

   (Unaudited)     
   December 31,   June 30, 
   2015   2015 
         
Current assets:          
Cash and cash equivalents  $1,638,462   $2,039,946 
Accounts receivable, net of allowances of $170,000   3,722,126    3,574,674 
Inventories, net   9,098,244    9,190,911 
Income tax receivable   22,262    12,487 
Other current assets   352,682    328,756 
           
Total current assets   14,833,776    15,146,774 
           
Property, plant and equipment, net   7,316,436    7,821,206 
Deferred income taxes   1,922,095    1,889,872 
Other assets, net   103,839    131,615 
           
Total assets  $24,176,146   $24,989,467 

 

See accompanying Notes to Financial Statements.

 

(CONTINUED)

 

 4 

 

 

ALLIED HEALTHCARE PRODUCTS, INC.

BALANCE SHEET

(CONTINUED)

LIABILITIES AND STOCKHOLDERS' EQUITY

 

   (Unaudited)     
   December 31,   June 30, 
   2015   2015 
         
Current liabilities:          
Accounts payable  $1,973,083   $1,368,797 
Other accrued liabilities   2,070,178    2,159,566 
Deferred income taxes   795,079    767,907 
Total current liabilities   4,838,340    4,296,270 
           
Commitments and contingencies          
           
Stockholders' equity:          
Preferred stock; $0.01 par value; 1,500,000 shares authorized; no shares issued and outstanding   -    - 
Series A preferred stock; $0.01 par value; 200,000 shares authorized; no shares issued and outstanding   -    - 
Common stock; $0.01 par value; 30,000,000 shares authorized; 10,427,878 shares issued at December 31, 2015 and June 30, 2015;  8,027,147 shares outstanding at December 31, 2015 and June 30, 2015   104,279    104,279 
Additional paid-in capital   48,429,601    48,546,670 
Accumulated deficit   (8,215,286)   (6,976,964)
Less treasury stock, at cost; 2,400,731 shares at          
December 31, 2015 and June 30, 2015, respectively   (20,980,788)   (20,980,788)
Total stockholders' equity   19,337,806    20,693,197 
Total liabilities and stockholders' equity  $24,176,146   $24,989,467 

 

See accompanying Notes to Financial Statements.

 

 5 

 

 

ALLIED HEALTHCARE PRODUCTS, INC.

STATEMENT OF CASH FLOWS

(UNAUDITED)

 

   Six months ended 
   December 31, 
   2015   2014 
         
Cash flows from operating activities:          
Net loss  $(1,238,322)  $(752,925)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:          
           
Depreciation and amortization   631,844    667,127 
Stock based compensation   1,788    2,853 
Provision for doubtful accounts and sales returns and allowances   2,860    27,838 
Deferred taxes   (123,907)   - 
           
Changes in operating assets and liabilities:          
Accounts receivable   (150,311)   415,105 
Inventories   92,667    (213,351)
Income tax receivable   (9,775)   (10,424)
Other current assets   (23,926)   (140,094)
Accounts payable   604,287    138,995 
Other accrued liabilities   (89,389)   123,055 
Net cash provided by (used in) operating activities   (302,184)   258,179 
           
           
Cash flows from investing activities:          
Capital expenditures   (99,300)   (86,088)
Net cash used in investing activities   (99,300)   (86,088)
           
           
Net increase (decrease) in cash and cash equivalents   (401,484)   172,091 
Cash and cash equivalents at beginning of period   2,039,946    1,366,762 
Cash and cash equivalents at end of period  $1,638,462   $1,538,853 

 

See accompanying Notes to Financial Statements.

 

 6 

 

 

ALLIED HEALTHCARE PRODUCTS, INC.

NOTES TO FINANCIAL STATEMENTS

(UNAUDITED)

 

1. Summary of Significant Accounting and Reporting Policies

 

Basis of Presentation

 

The accompanying unaudited financial statements of Allied Healthcare Products, Inc. (the “Company”) have been prepared in accordance with the instructions for Form 10-Q and do not include all of the information and disclosures required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, all adjustments, consisting only of normal recurring adjustments considered necessary for a fair presentation, have been included. Operating results for any quarter are not necessarily indicative of the results for any other quarter or for the full year. These statements should be read in conjunction with the financial statements and notes to the financial statements thereto included in the Company’s Annual Report on Form 10-K for the year ended June 30, 2015.

 

Recently Issued Accounting Guidance

 

In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU” or “Update”) No. 2014-09, “Revenue from Contracts with Customers.” This ASU is a comprehensive new revenue recognition model that requires a company to recognize revenue to depict the transfer of goods or services to a customer at an amount that reflects the consideration it expects to receive in exchange for those goods or services. This ASU is effective for annual reporting periods beginning after December 15, 2016 and early adoption is not permitted. On July 9, 2015 the FASB voted to defer the effective date of this standard by one year to December 15, 2017 for the interim and annual reporting periods beginning after that date and permitted early adoption of the standard, but not before the original effective date of December 15, 2016. Companies may use either a full retrospective or modified retrospective approach to adopt this ASU. We are currently evaluating which transition approach to use and the full impact this ASU will have on our future financial statements.

 

In August 2014, the FASB issued ASU No. 2014-15, to communicate amendments to FASB Account Standards Codification Subtopic 205-40, “Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern.” The ASU requires management to evaluate relevant conditions, events and certain management plans that are known or reasonably knowable as of the evaluation date when determining whether substantial doubt about an entity’s ability to continue as a going concern exists. Management will be required to make this evaluation for both annual and interim reporting periods. Management will have to make certain disclosures if it concludes that substantial doubt exists or when it plans to alleviate substantial doubt about the entity’s ability to continue as a going concern. The standard is effective for annual periods ending after December 15, 2016 and for interim reporting periods starting in 2017. Early adoption is permitted. We currently believe there will be no impact on our financial statement disclosures.

 

 7 

 

 

In April 2015, the FASB issued ASU No. 2015-03, “Interest – Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs”.  This ASU requires companies to present debt issuance costs as a direct deduction from the carrying value of that debt liability. ASU 2015-03 does not impact the recognition and measurement guidance for debt issuance costs.  This ASU was further amended by ASU No. 2015-15, “Interest-Imputation of Interest” to provide guidance with respect to debt issuance costs associated with line-of-credit arrangements. These ASUs are effective for annual reporting periods beginning after December 15, 2015 and early adoption is permitted. Accordingly, we will adopt this ASU on July 1, 2016.  When implementing this ASU companies are required to use a retrospective approach and we are currently evaluating the impact to our future financial statements.

 

In July 2015, the FASB issued ASU No. 2015-11 to simplify the subsequent measurement of inventory. Under this new standard, an entity should measure inventory at the lower of cost and net realizable value. Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2016. The amendments in this guidance should be applied prospectively with earlier application permitted as of the beginning of an interim or annual reporting period. The Company is currently evaluating the impact to our future financial statements.

 

In November 2015, the FASB issued ASU 2015-17, Balance Sheet Classification of Deferred Taxes (Topic 740). This update requires that entities with a classified balance sheet present all deferred tax assets and liabilities as noncurrent. This update is effective for annual and interim periods for fiscal years beginning after December 15, 2016, which will require us to adopt these provisions in the first quarter of fiscal 2018. Early adoption is permitted for financial statements that have not been previously issued. This update can be applied on either a prospective or retrospective basis. We do not expect the adoption of this update to have a material impact on our consolidated financial statements.

 

Fair Value of Financial Instruments

 

The Company’s financial instruments consist of cash and cash equivalents, accounts receivable and accounts payable. The carrying amounts for cash and cash equivalents, accounts receivable and accounts payable approximate their fair value due to the short maturity of these instruments.

 

 8 

 

 

2. Inventories

 

Inventories are comprised as follows:

 

   December 31, 2015   June 30, 2015 
         
Work-in progress  $600,973   $545,410 
Component parts   7,699,292    7,721,413 
Finished goods   2,264,931    2,397,044 
Reserve for obsolete and excess inventory   (1,466,952)   (1,472,956)
   $9,098,244   $9,190,911 

 

3. Earnings per share

 

Basic earnings per share are based on the weighted average number of shares of all common stock outstanding during the period. Diluted earnings per share are based on the sum of the weighted average number of shares of common stock and common stock equivalents outstanding during the period. The number of basic and diluted shares outstanding for the three and six months ended December 31, 2015 and 2014 were 8,027,147.

 

4. Commitments and Contingencies

 

Legal Claims

 

The Company is subject to various investigations, claims and legal proceedings covering a wide range of matters that arise in the ordinary course of its business activities. The Company intends to continue to conduct business in such a manner as to avert any FDA action seeking to interrupt or suspend manufacturing or require any recall or modification of products.

 

The Company has recognized the costs and associated liabilities only for those investigations, claims and legal proceedings for which, in its view, it is probable that liabilities have been incurred and the related amounts are estimable. Based upon information currently available, management believes that existing accrued liabilities are sufficient.

 

Stuyvesant Falls Power Litigation. The Company is currently involved in litigation with Niagara Mohawk Power Corporation d/b/a National Grid (“Niagara”) and other parties, which provides electrical power to the Company’s facility in Stuyvesant Falls, New York. In fiscal year 2011, Niagara began sending invoices to the Company for electricity used at the Company’s Stuyvesant Falls plant. The Company maintains in its defense of the lawsuit that it is entitled to a certain amount of free electricity based on covenants running with the land which have been honored for more than a century. Niagara’s attempts to collect such invoices were stopped in December 2010 by a temporary restraining order, although a court has not yet ruled on the merits of all of Niagara’s claims. Among other things, Niagara seeks as damages the value of electricity received by the Company without charge. While the total value of electricity at issue in the litigation is not known with certainty, Niagara alleges in its Motion For Summary Judgment, filed on March 14, 2014, damages of approximately $492,000 in free electricity since May 2010. Alternatively, Niagara asserts that, in the event that the free power covenant is still enforceable, the Company is still responsible for delivery fees relating to any free power to which it is entitled. The Company filed its own Motion For Summary Judgment on March 14, 2014, seeking dismissal of Niagara’s claims and oral arguments on the motions were held on June 13, 2014. On October 1, 2014, the Court granted the Company’s motion, denied Niagara’s motion and ruled that the Company is entitled to receive electrical power pursuant to the power covenants. On October 26 and October 30, 2014, Niagara and other parties filed separate notices of appeal of the Court’s decision. A settlement hearing occurred on March 19, 2015, but no settlement has been reached. The parties’ respective appeal briefs have been filed and arguments occurred on February 11, 2016 before the Supreme Court of New York, Appellate Division, Third Department. As of December 31, 2015, the Company has not recorded a provision for this matter given management’s assessment of the probability of a loss.

 

 9 

 

 

Dräger Patent Litigation. On or about October 4, 2013, Dräger Medical GmbH and certain affiliates (the “Dräger Plaintiffs”) filed a patent infringement lawsuit against the Company in the District of Delaware (the “2013 Dräger Suit”), asserting that the Company infringes United States Patent Nos. 7,487,776 and 8,286,633 (the “‘633 Patent”), both protecting particular combinations of carbon dioxide absorption cartridges and adapters which fit on anesthesia machines. The Dräger Plaintiffs assert that the Company’s sales of certain models of its Litholyme and Carbolime single-use carbon dioxide absorption cartridges infringe both patents. The Company answered the Complaint, asserting invalidity of the patents, non-infringement, and implied license under the doctrine of permissive repair.

 

On October 25, 2013, the Dräger Plaintiffs filed a motion for preliminary injunction requesting that the Company be enjoined from selling certain models of its Litholyme and Carbolime cartridges during the pendency of the litigation. A hearing on the motion for preliminary injunction was held on February 7, 2014. On March 24, 2014, the Court ruled in Allied’s favor and denied Dräger’s motion for a preliminary injunction, stating among other things that Dräger had not carried its burden of showing that Allied had infringed Dräger’s patents. On June 20, 2014, the Company filed a motion seeking summary judgment based on the repair doctrine, which was the basis for the Court’s denial of Dräger’s motion for preliminary injunction. On March 27, 2015, the Court granted the Company’s motion for summary judgment of non-infringement. The Dräger Plaintiffs appealed the Court’s Order granting the motion for summary judgment on April 21, 2015 and briefs have been filed by both sides.

 

On October 13, 2015, the Dräger Plaintiffs filed a new patent infringement lawsuit (the “2015 Dräger Suit”) against the Company in the District of Delaware asserting that the Company infringes United States Reissue Patent No. RE45745, a reissue of the ‘633 Patent. The New Lawsuit alleged that the Company’s sales of the “Dräger Style” models of its Litholyme and Carbolyme single-use carbon dioxide absorption cartridges infringe the claims of the reissued patent.

 

 10 

 

 

On January 29, 2016, the Company and the Dräger Plaintiffs resolved the 2013 Dräger Suit and the 2015 Dräger Suit pursuant to a mutually satisfactory settlement agreement. The appeal of the 2013 Dräger Suit was dismissed on February 1, 2016 and the 2015 Dräger Suit was resolved by a consent judgement and permanent injunction on February 12, 2016. The Company will not be required to make any payments under the settlement agreement, however, it discontinued the manufacture of Dräger Style models of its Litholyme and Carbolyme single-use carbon dioxide absorption cartridges as of October 13, 2015. The Company does not believe that this settlement agreement will have a material effect on its business, financial position, results of operations or cash flows.

 

Employment Contract

 

The Company has entered into an employment contract with its chief executive officer with annual renewals. The contract includes termination without cause and change of control provisions, under which the chief executive officer is entitled to receive specified severance payments generally equal to two times ending annual salary if the Company terminates his employment without cause or he voluntarily terminates his employment with “good reason.” “Good Reason” generally includes changes in the scope of his duties or location of employment but also includes (i) the Company’s written election not to renew the Employment Agreement and (ii) certain voluntary resignations by the chief executive officer following a “Change of Control” as defined in the Agreement.

 

5. Financing

 

As of December 31, 2015, the Company is party to a Loan and Security Agreement, dated November 17, 2009, with Enterprise Bank & Trust (the “Credit Agreement”) pursuant to which the Company obtained a secured revolving credit facility. Currently, the agreement provides for borrowing availability of up to $5,000,000 (the “Credit Facility”). The Company’s obligations under the Credit Facility are secured by certain assets of the Company pursuant to the terms and subject to the conditions set forth in the Credit Agreement.

 

The Credit Agreement was amended on November 9, 2015 extending the maturity date to November 9, 2016. Subject to the conditions and limitations set forth in the Credit Agreement, the Credit Facility will be available on a revolving basis until it expires on November 9, 2016, at which time all amounts outstanding under the Credit Facility will be due and payable. Advances under the Credit Facility will be made pursuant to a Revolving Credit Note (as defined in the Credit Agreement) executed by the Company in favor of Enterprise Bank & Trust. Such advances will bear interest at a rate equal to 3.50% in excess of the 30-day LIBOR rate. Advances may be prepaid in whole or in part without premium or penalty.

 

 11 

 

 

While the Credit Agreement provides for stated availability of $5.0 million, in connection with renewal on November 9, 2015, a new covenant was added requiring the Company to maintain minimum “liquidity” of $1.25 million. Liquidity is defined as the difference between cash and cash equivalents and the aggregate principal balance of borrowings under the Credit Agreement and is measured at the last day of each fiscal quarter, commencing on December 31, 2015. Based on the Company’s cash and cash equivalents as of December 31, the Company would only be permitted to borrow up to $.39 million as of such date. Decreases in the Company’s cash position will effectively reduce the amount the Company is able to borrow and/or require accelerated repayments.

 

Under the Credit Agreement, advances are generally subject to customary borrowing conditions. The Credit Agreement also contains covenants with which the Company must comply during the term of the Credit Facility. Among other things, such covenants restrict the Company’s ability to incur certain additional debt; make specified restricted payments, dividends and capital expenditures; authorize or issue capital stock; enter into certain transactions with affiliates; consolidate or merge with or acquire another business; sell certain of its assets or dissolve or wind up the Company. In addition, effective November 9, 2015, the Credit Agreement includes the minimum liquidity requirement described above. The Credit Agreement also contains certain events of default that are customary for financings of this type including, without limitation: the failure to pay principal, interest, fees or other amounts when due; the breach of specified representations or warranties contained in the loan documents; cross-default with certain other indebtedness of the Company; the entry of uninsured judgments that are not bonded or stayed; failure to comply with the observance or performance of specified agreements contained in the loan documents; commencement of bankruptcy or other insolvency proceedings; and the failure of any of the loan documents entered into in connection with the Credit Facility to be in full force and effect. After an event of default, and upon the continuation thereof, the principal amount of all loans made under the Credit Facility would bear interest at a rate per annum equal to 4.00% above the otherwise applicable interest rate (provided, that the interest rate may not exceed the highest rate permissible under law), and the lender would have the option to accelerate maturity and payment of the Company’s obligations under the Credit Facility.

 

The 30-day LIBOR rate was 0.42% on December 31, 2015.

 

At December 31, 2015, the Company had no aggregate indebtedness, including capital lease obligations, short-term debt and long term debt.

 

The Company was in compliance with all of the covenants associated with the Credit Facility at December 31, 2015.

 

 12 

 

 

6. Income Taxes

 

The Company accounts for income taxes under ASC Topic 740: “Income Taxes.” Under ASC 740, the deferred tax provision is determined using the liability method, whereby deferred tax assets and liabilities are recognized based upon temporary differences between the financial statement and income tax bases of assets and liabilities using presently enacted tax rates. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized.  In the three and six months ended December 31, 2015 the Company recorded the tax benefit of losses incurred in the amount of approximately $214,000 and $427,000, respectively.  As the realization of the tax benefit of the net operating loss is not assured, an additional valuation allowance of approximately $214,000 and $427,000, net of the effect of the deferred taxes in the amount of $44,000 and ($45,000), for the three and six months ended respectively, was also recorded. As a result of the expiration of tax benefits associated with expiring stock options not previously covered by the valuation allowance, the Company recorded a deferred tax benefit in the amount of approximately $0 and $124,000 for the three and six months ended respectively. For the three and six months ended December 31, 2014, the Company recorded the tax benefit of losses incurred in the amount of $12,000 and $278,000 net of additions to the valuation allowance of like amounts.  The total valuation allowance recorded by the Company as of December 31, 2015 and 2014 was approximately $1,677,000 and $1,078,000, respectively.  To the extent that the Company’s losses continue in future quarters, the tax benefit of those losses will be subject to a valuation allowance.

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

Results of Operations

 

Three months ended December 31, 2015 compared to three months ended December 31, 2014

 

Allied had net sales of $8.8 million for the three months ended December 31, 2015, down $0.2 million from net sales of $9.0 million in the prior year same quarter resulting from lower orders and customer releases for shipment. Domestic sales were up 1.1% while international sales, which represented 25.0% of second quarter sales, were down 9.2% from the prior year same quarter.

 

Orders for the Company’s products for the three months ended December 31, 2015 of $8.1 million were $1.0 million or 11.0% lower than orders for the prior year same quarter of $9.1 million. Domestic orders are down 10.4% over the prior year same quarter while international orders, which represented 26.1% of second quarter orders, were 12.3% lower than orders for the prior year same quarter. International orders have been negatively impacted by currency devaluations in Central and South America. The Company continues to believe that domestic purchases of equipment and durable goods and the purchase of equipment by hospitals and municipalities have been cut to meet budgets and conserve cash due to the slow recovery of the economy since the recession in 2008 and uncertainty regarding the impact of the Affordable Care Act. Orders and sales remain below pre-recession levels.

 

 13 

 

 

Gross profit for the three months ended December 31, 2015 was $1.8 million, or 20.5% of net sales, compared to $2.2 million, or 24.4% of net sales, for the three months ended December 31, 2014. The $0.4 million decrease in gross profit is attributable to the decrease in sales, the related lower production levels and less effective utilization of fixed overhead cost, and product mix.

 

Selling, general and administrative expenses for the three months ended December 31, 2015 were $2.5 million compared to selling, general and administrative expenses of $2.2 million for the three months ended December 31, 2014. Legal expenses are approximately $171,000 higher than in the prior year and salaries and benefit expenses are approximately $51,000 higher than in the prior year.

 

Loss from operations was $687,748 for the three months ended December 31, 2015 compared to loss from operations of $35,016 for the three months ended December 31, 2014.

 

Allied had a loss before benefit from income taxes in the second quarter of fiscal 2016 of $708,764 compared to loss before benefit from income taxes in the second quarter of fiscal 2015 of $44,750.  The Company recorded a tax benefit of $0 for the three months ended December 31, 2015 and 2014.  In the quarter ended December 31, 2015, the tax benefit of losses in the amount of approximately $214,000, net of the effect of deferred taxes in the amount of $44,000, was fully offset by a valuation allowance of equivalent amount.   To the extent that the Company’s losses continue in future quarters, the tax benefit of those losses will be fully offset by a valuation allowance.

 

Net loss for the second quarter of fiscal 2016 was $708,764 or $0.09 per basic and diluted share compared to net loss of $44,750 or $0.01 per basic and diluted share for the second quarter of fiscal 2015. The weighted average number of common shares outstanding, used in the calculation of basic and diluted earnings per share for the second quarters of fiscal 2016 and 2015 were 8,027,147.

 

Six months ended December 31, 2015 compared to six months ended December 31, 2014

 

Allied had net sales of $17.3 million for the six months ended December 31, 2015, down $0.5 million, or 2.8% from net sales of $17.8 million in the prior year same period resulting from lower order levels and a decrease in customer orders released for shipment. Domestic sales were up 1.4% from the prior year same period while international sales were down 15.4% from the prior year same period. International business represented 22.9% of sales for the first six months of fiscal 2016. The drop in international sales reflects the decrease in international orders.

 

Orders for the Company’s products for the six months ended December 31, 2015 of $16.4 million were $2.1 million or 11.4% lower than orders for the prior year same period of $18.5 million. Domestic orders are down 4.2% over the prior year same period while international orders, which represented 22.4% of orders for the first six months of fiscal 2016, were 28.5% lower than orders for the prior year same period. The Company believes that the decrease in International orders is primarily a result of currency devaluations in Central and South America.

 

 14 

 

 

Gross profit for the six months ended December 31, 2015 was $3.5 million, or 20.2% of net sales, compared to $3.7 million, or 20.8% of net sales, for the six months ended December 31, 2014. The $0.2 million decrease in gross profit is primarily attributable to the decrease in sales.

 

Selling, general and administrative expenses for the six months ended December 31, 2015 were $4.8 million compared to selling, general and administrative expenses of $4.5 million for the six months ended December 31, 2014. Legal expenses are approximately $348,000 higher than in the prior year.

 

Loss from operations was $1.3 million for the six months ended December 31, 2015 compared to loss from operations of $732,521 for the six months ended December 31, 2014.

 

Allied had loss before benefit from income taxes in the first six months of fiscal 2016 of $1,362,229, compared to loss before benefit from income taxes in the first six months of fiscal 2015 of $752,925. The Company’s tax provision net of valuation allowance reflects a tax benefit of $123,907 for the six months ended December 31, 2015 compared to a tax benefit of $0 for the six months ended December 31, 2014. In the six months ended December 31, 2015, the tax benefit of losses in the amount of approximately $427,000, net of the effect of deferred taxes in the amount of ($45,000), was fully offset by a valuation allowance of equivalent amount. As a result of the expiration of tax benefits associated with expiring stock options not previously covered by the valuation allowance, the Company recorded a deferred tax benefit in the amount of approximately $124,000.  To the extent that the Company’s losses continue in future quarters, the tax benefit of those losses will be fully offset by a valuation allowance.

 

Net loss for the six months ended December 31, 2015 was $1,238,322 or $0.15 per basic and diluted share compared to net loss of $752,925 or $0.09 per basic and diluted share for the first six months of fiscal 2015. The weighted average number of common shares outstanding, used in the calculation of basic and diluted earnings per share for the first six months of fiscal 2016 and 2015 was 8,027,147.

 

Liquidity and Capital Resources

 

The Company believes that available resources, including availability under a credit facility described below, are sufficient to meet operating requirements in the coming year.

 

 15 

 

 

The Company’s working capital was $10.0 million at December, 2015 compared to $10.9 million at June 30, 2015. Accounts Receivable increased by approximately $0.1 million and Other Accrued Liabilities decreased by approximately $0.1 million. During fiscal 2016, these increases in working capital were offset by a $0.4 million decrease in Cash and Cash Equivalents and a $0.6 million increase in Accounts Payable. Accounts Payable and Other Accrued Liabilities are subject to normal fluctuations in purchasing levels and the timing of payments within the quarter. Accounts Receivable was $3.7 million at December 31, 2015, an increase from $3.6 million at June 30, 2015. Accounts Receivable as measured in days sales outstanding (“DSO”) was 40 DSO at December 31, 2015; an increase from 37 DSO at June 30, 2015. The Company does adjust product forecast, order quantities and safety stock based on changes in demand patterns in order to manage inventory levels.

 

The Company is party to a Loan and Security Agreement, dated November 17, 2009, with Enterprise Bank & Trust (the “Credit Agreement”). At December 31, 2015, the Company had $5,000,000 available for borrowing on the line of credit (the “Credit Facility”). On November 9, 2015, the Credit Agreement was amended to include a covenant requiring that the Company maintain minimum “liquidity” of $1.25 million. Liquidity is defined as the difference between cash and cash equivalents and the aggregate principal balance of borrowings under the Credit Agreement, measured on the last day of the fiscal quarter commencing on December 31, 2015. Based on the Company’s cash and cash equivalents as of December, the Company would only be permitted to borrow up to $.39 million as of such date. Decreases in the Company’s cash position will effectively reduce the amount the Company is able to borrow and/or require accelerated repayments.

 

The Company’s obligations under the Credit Facility are secured by certain assets of the Company pursuant to the terms and subject to the conditions set forth in the Credit Agreement. See Note 5 – Financing to the Company’s unaudited financial statements for more information concerning the Credit Facility. Any advances under the Credit Facility will be made pursuant to a Revolving Credit Note (as defined in the Credit Agreement) executed by the Company in favor of the bank. Such advances will bear interest at a rate equal to the 30-day LIBOR rate plus 3.50%. Advances may be prepaid in whole or in part without premium or penalty. The 30-day LIBOR rate was 0.42% on December 31, 2015.

 

Management has implemented cost saving measures which have reduced the Company’s expenses, including overhead reductions and deferral of non-essential capital expenditures. While there are no assurances that these measures will continue to be successful, management believes that the Company currently has sufficient liquidity given its cash needs. If the Company’s cost saving measures are not successful in the long term, the Company may need to borrow under the Credit Agreement or obtain other debt financing to fund its operations. There is no assurance that the Company will be able to borrow sufficient amounts under the Credit Agreement, as amended on November 9, 2015. Even if the Company were able to borrow under the Credit Agreement, the Credit Agreement expires on November 9, 2016, at which time any outstanding borrowings would be due and payable, with interest. If the Company does not have sufficient cash to repay any outstanding principal and interest under the Credit Agreement, it would be required to refinance the Credit Facility. The Company believes that in either such event it would have a sufficient borrowing base to secure the necessary financing, however the Company could incur additional costs due to higher interest rates or fees. At December 31, 2015, the Company had no aggregate indebtedness, including capital lease obligations, short-term debt and long term debt.

 

 16 

 

 

Inflation has not had a material effect on the Company’s business or results of operations during the first six months of fiscal 2016.

 

Litigation and Contingencies

 

The Company becomes, from time to time, a party to personal injury litigation arising out of incidents involving the use of its products. The Company believes that any potential judgments resulting from these claims over its self-insured retention will be covered by the Company’s product liability insurance. See Part II, Item 1 – Legal Proceedings, below, for more information concerning litigation.

 

Critical Accounting Policies

 

The impact and any associated risks related to the Company’s critical accounting policies on business operations are discussed throughout “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” where such policies affect the Company’s reported and expected financial results. For a detailed discussion on the application of these and other accounting policies, see the Company’s Annual Report on Form 10-K for the year ended June 30, 2015.

 

Recently Issued Accounting Guidance

 

See Note 1 – Summary of Significant Accounting and Reporting Policies for more information on recent accounting pronouncements and their impact, if any, on the Company’s financial statements. Management believes there have been no material changes to our critical accounting policies.

 

Item 3. Quantitative and Qualitative Disclosure about Market Risk

 

At December 31, 2015, the Company did not have any debt outstanding. The revolving credit facility bears an interest rate using the 30-day LIBOR rate as the basis, as defined in the loan agreement, and therefore is subject to additional expense should there be an increase in market interest rates while borrowing on the revolving credit facility.

 

The Company had no holdings of derivative financial or commodity instruments at December 31, 2015. The Company has international sales; however these sales are denominated in U.S. dollars, mitigating foreign exchange rate fluctuation risk.

 

 17 

 

 

Item 4. Controls and Procedures

 

Evaluation of Disclosure Controls and Procedures

 

The Company maintains controls and procedures designed to ensure that information required to be disclosed in the reports that the Company files or submits under the Securities Exchange Act of 1934 is recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the Securities and Exchange Commission and that such information is accumulated and communicated to the Company's management, including its Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. Based upon their evaluation of those controls and procedures performed as of December 31, 2015, the Chief Executive Officer and Chief Financial Officer of the Company concluded that its disclosure controls and procedures were effective.

 

Changes in internal control over financial reporting

 

There were no changes in the Company’s internal control over financial reporting during the quarter ended December 31, 2015 that have materially affected, or are reasonably likely to materially affect, the registrant’s internal control over financial reporting.

 

Part II. OTHER INFORMATION

 

Item 1.   Legal Proceedings

 

Dräger Patent Litigation. On or about October 4, 2013, Dräger Medical GmbH and certain affiliates (the “Dräger Plaintiffs”) filed a patent infringement lawsuit against the Company in the District of Delaware, asserting that the Company infringes United States Patent Nos. 7,487,776 and 8,286,633 (the “‘633 Patent”), both protecting particular combinations of carbon dioxide absorption cartridges and adapters which fit on anesthesia machines (the “2013 Dräger Suit”). The Dräger Plaintiffs assert that the Company’s sales of certain models of its Litholyme and Carbolime single-use carbon dioxide absorption cartridges infringe both patents. The Company answered the Complaint, asserting invalidity of the patents, non-infringement, and implied license under the doctrine of permissive repair.

 

On October 25, 2013, the Dräger Plaintiffs filed a motion for preliminary injunction requesting that the Company be enjoined from selling certain models of its Litholyme and Carbolime cartridges during the pendency of the litigation. A hearing on the motion for preliminary injunction was held on February 7, 2014. On March 24, 2014, the Court ruled in Allied’s favor and denied Dräger’s motion for a preliminary injunction, stating among other things that Dräger had not carried its burden of showing that Allied had infringed Dräger’s patents. On June 20, 2014, the Company filed a motion seeking summary judgment based on the repair doctrine, which was the basis for the Court’s denial of Dräger’s motion for preliminary injunction. On March 27, 2015, the Court granted the Company’s motion for summary judgment of non-infringement. The Dräger Plaintiffs appealed the Court’s Order granting the motion for summary judgment on April 21, 2015 and briefs have been filed by both sides.

 

 18 

 

 

On October 13, 2015, the Dräger Plaintiffs filed a new patent infringement lawsuit (the “2015 Dräger Suit”) against the Company in the District of Delaware asserting that the Company infringes United States Reissue Patent No. RE45745, a reissue of the ‘633 Patent. The New Lawsuit alleges that the Company’s sales of the “Dräger Style” models of its Litholyme and Carbolyme single-use carbon dioxide absorption cartridges infringe the claims of the reissued patent.

 

On January 29, 2016, the Company and the Dräger Plaintiffs resolved the 2013 Dräger Suit and the 2015 Dräger Suit pursuant to a mutually satisfactory settlement agreement. The appeal of the 2013 Dräger Suit was dismissed on February 1, 2016 and the 2015 Dräger Suit was resolved by a consent judgement and permanent injunction on February 12, 2016. The Company will not be required to make any payments under the settlement agreement, however, it discontinued the manufacture of “Dräger Style” models of its Litholyme and Carbolyme single-use carbon dioxide absorption cartridges as of October 13, 2015. The Company does not believe that this settlement agreement will have a material effect on its business, financial position, results of operations or cash flows.

 

Item 6.   Exhibits

 

(a) Exhibits:

 

31.1 Certification of Chief Executive Officer (filed herewith)

 

31.2 Certification of Chief Financial Officer (filed herewith)

 

32.1 Sarbanes-Oxley Certification of Chief Executive Officer (furnished herewith)*

 

32.2 Sarbanes-Oxley Certification of Chief Financial Officer (furnished herewith)*

 

101.INS XBRL Instance Document**

 

101.SCH XBRL Taxonomy Extension Schema Document**

 

101.CAL XBRL Taxonomy Extension Calculation Linkbase Document**

 

101.DEF XBRL Taxonomy Extension Definition Linkbase Document**

 

101.LAB XBRL Taxonomy Extension Label Linkbase Document**

 

101.PRE XBRL Taxonomy Extension Presentation Linkbase Document**

 

*Notwithstanding any incorporation of this Quarterly Report on Form 10-Q in any other filing by the Registrant, Exhibits furnished herewith and designated with an asterisk (*) shall not be deemed incorporated by reference to any other filing under the Securities Act of 1933 or the Securities Exchange Act of 1934 unless specifically otherwise set forth therein.

 

**Filed herewith as Exhibit 101 are the following materials formatted in XBRL: (i) Statement of Operations, (ii) Balance Sheet, (iii) Statement of Cash Flows and (iv) Notes to Financial Statements.

 

 19 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  ALLIED HEALTHCARE PRODUCTS, INC.
   
  /s/ Daniel C. Dunn
  Daniel C. Dunn
  Chief Financial Officer
   
  Date: February 16, 2016

 

 20 

 EX-31.1 2 v430780_ex31-1.htm EXHIBIT 31.1

 

Exhibit 31.1

 

CERTIFICATION

 

I, EARL R. REFSLAND, certify that:

 

1. I have reviewed this Form 10-Q of ALLIED HEALTHCARE PRODUCTS, INC.;

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c. Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d. Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

 

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

 

a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

 

b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

 

Date: February 16, 2016

  /s/ EARL R. REFSLAND
  Earl. R. Refsland
  President & Chief Executive Officer

 

  

 EX-31.2 3 v430780_ex31-2.htm EXHIBIT 31.2

 

Exhibit 31.2

CERTIFICATION

 

I, DANIEL C. DUNN, certify that:

 

1. I have reviewed this Form 10-Q of ALLIED HEALTHCARE PRODUCTS, INC.;

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c. Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d. Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

 

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

 

a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

 

b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

 

Date: February 16, 2016  
  /s/ DANIEL C. DUNN
  Daniel C. Dunn
  Vice President, Chief Financial Officer & Secretary

 

  

 EX-32.1 4 v430780_ex32-1.htm EXHIBIT 32.1

 

Exhibit 32.1

 

CERTIFICATION Pursuant to 18 U.S.C. § 1350

 

The undersigned officer of ALLIED HEALTHCARE PRODUCTS, INC. (the "Company"), hereby certifies, to such officer's knowledge, that the Company's Quarterly Report on Form 10-Q for the Company’s fiscal quarter ended December 31, 2015 (the "Report") fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934 and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

  /s/ Earl R. Refsland
  Earl R. Refsland
  President & Chief Executive Officer
February 16, 2016  

 

  

 EX-32.2 5 v430780_ex32-2.htm EXHIBIT 32.2

 

Exhibit 32.2

 

CERTIFICATION Pursuant to 18 U.S.C. § 1350

 

The undersigned officer of ALLIED HEALTHCARE PRODUCTS, INC. (the "Company"), hereby certifies, to such officer's knowledge, that the Company's Quarterly Report on Form 10-Q for the Company’s fiscal quarter ended December 31, 2015 (the "Report") fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934 and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

  /s/ Daniel C. Dunn
  Daniel C. Dunn
  Vice President, Chief Financial Officer & Secretary
February 16, 2016  

 

  

 EX-101.INS 6 ahpi-20151231.xml XBRL INSTANCE DOCUMENT 0000874710 2016-01-30 0000874710 2015-06-30 0000874710 2014-07-01 2014-12-31 0000874710 2015-07-01 2015-12-31 0000874710 2014-10-01 2014-12-31 0000874710 2015-10-01 2015-12-31 0000874710 2015-11-01 2015-11-09 0000874710 2015-11-09 0000874710 2009-11-17 0000874710 2014-12-31 0000874710 2015-12-31 0000874710 2014-06-30 0000874710 us-gaap:SeriesAPreferredStockMember 2015-12-31 0000874710 us-gaap:SeriesAPreferredStockMember 2015-06-30 0000874710 ahpi:NiagaraMember 2014-03-01 2014-03-14 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure 10-Q false 2015-12-31 2016 Q2 ALLIED HEALTHCARE PRODUCTS INC 0000874710 --06-30 Smaller Reporting Company AHPI 8027147 799 838 -10533 -21854 8999662 8846359 6841177 7067748 2158485 1778611 2193501 2466359 -35016 -687748 0 0 -44750 -708764 -44750 -708764 1554 1902 -21958 -41662 17844929 17309196 14111661 13832294 3733268 3476902 4465789 4799371 -732521 -1322469 0 -123907 -752925 -1238322 -752925 -1362229 7821206 1922095 1889872 103839 131615 24176146 24989467 1638462 2039946 3722126 3574674 9098244 9190911 22262 12487 352682 328756 14833776 15146774 7316436 1973083 1368797 2070178 2159566 4838340 4296270 0 0 0 0 104279 104279 48429601 48546670 -8215286 -6976964 20980788 20980788 19337806 20693197 24176146 24989467 795079 767907 667127 631844 2853 1788 27838 2860 0 -123907 -415105 150311 213351 -92667 10424 9775 -302184 86088 99300 -86088 -99300 172091 -401484 1366762 1538853 140094 23926 138995 604287 123055 -89389 258179 600973 545410 7699292 7721413 2264931 2397044 1466952 1472956 8027147 492000 5000000 0.0350 5000000 0.0400 0.0042 <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="center"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"> <b>1. Summary of Significant Accounting and Reporting Policies</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"> <b>&#160;</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"> <b><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Basis of Presentation</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The accompanying unaudited financial statements of Allied Healthcare Products, Inc. (the &#8220;Company&#8221;) have been prepared in accordance with the instructions for Form 10-Q and do not include all of the information and disclosures required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, all adjustments, consisting only of normal recurring adjustments considered necessary for a fair presentation, have been included. Operating results for any quarter are not necessarily indicative of the results for any other quarter or for the full year. These statements should be read in conjunction with the financial statements and notes to the financial statements thereto included in the Company&#8217;s Annual Report on Form 10-K for the year ended June 30, 2015.</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"> <font style="FONT-WEIGHT: normal">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><b><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Recently Issued Accounting Guidance</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">In May 2014, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221; or &#8220;Update&#8221;) No. 2014-09, &#8220;Revenue from Contracts with Customers.&#8221; This ASU is a comprehensive new revenue recognition model that requires a company to recognize revenue to depict the transfer of goods or services to a customer at an amount that reflects the consideration it expects to receive in exchange for those goods or services. This ASU is effective for annual reporting periods beginning after December 15, 2016 and early adoption is not permitted. On July 9, 2015 the FASB voted to defer the effective date of this standard by one year to December 15, 2017 for the interim and annual reporting periods beginning after that date and permitted early adoption of the standard, but not before the original effective date of December 15, 2016. Companies may use either a full retrospective or modified retrospective approach to adopt this ASU. We are currently evaluating which transition approach to use and the full impact this ASU will have on our future financial statements.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">In August 2014, the FASB issued ASU No. 2014-15, to communicate amendments to FASB Account Standards Codification Subtopic 205-40, &#8220;Disclosure of Uncertainties about an Entity&#8217;s Ability to Continue as a Going Concern.&#8221; The ASU requires management to evaluate relevant conditions, events and certain management plans that are known or reasonably knowable as of the evaluation date when determining whether substantial doubt about an entity&#8217;s ability to continue as a going concern exists. Management will be required to make this evaluation for both annual and interim reporting periods. Management will have to make certain disclosures if it concludes that substantial doubt exists or when it plans to alleviate substantial doubt about the entity&#8217;s ability to continue as a going concern. The standard is effective for annual periods ending after December 15, 2016 and for interim reporting periods starting in 2017. Early adoption is permitted. We currently believe there will be no impact on our financial statement disclosures.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">In April 2015, the FASB issued ASU No. 2015-03, &#8220;Interest &#150; Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs&#8221;.&#160; This ASU requires companies to present debt issuance costs as a direct deduction from the carrying value of that debt liability. ASU 2015-03 does not impact the recognition and measurement guidance for debt issuance costs.&#160; This ASU was further amended by ASU No. 2015-15, &#8220;Interest-Imputation of Interest&#8221; to provide guidance with respect to debt issuance costs associated with line-of-credit arrangements. These ASUs are effective for annual reporting periods beginning after December 15, 2015 and early adoption is permitted. Accordingly, we will adopt this ASU on July 1, 2016.&#160; When implementing this ASU companies are required to use a retrospective approach and we are currently evaluating the impact to our future financial statements.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">In July 2015, the FASB issued ASU No. 2015-11 to simplify the subsequent measurement of inventory. Under this new standard, an entity should measure inventory at the lower of cost and net realizable value. Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2016. The amendments in this guidance should be applied prospectively with earlier application permitted as of the beginning of an interim or annual reporting period. The Company is currently evaluating the impact to our future financial statements.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px 0px 0px 0in; FONT: 10pt Times New Roman, Times, Serif" align="justify">In November 2015, the FASB issued ASU 2015-17, Balance Sheet Classification of Deferred Taxes (Topic 740). This update requires that entities with a classified balance sheet present all deferred tax assets and liabilities as noncurrent. This update is effective for annual and interim periods for fiscal years beginning after December 15, 2016, which will require us to adopt these provisions in the first quarter of fiscal 2018. Early adoption is permitted for financial statements that have not been previously issued. This update can be applied on either a prospective or retrospective basis. We do not expect the adoption of this update to have a material impact on our consolidated financial statements.</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.4in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"> <b><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Fair Value of Financial Instruments</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Company&#8217;s financial instruments consist of cash and cash equivalents, accounts receivable and accounts payable. The carrying amounts for cash and cash equivalents, accounts receivable and accounts payable approximate their fair value due to the short maturity of these instruments.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"> <b>Basis of Presentation</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The accompanying unaudited financial statements of Allied Healthcare Products, Inc. (the &#8220;Company&#8221;) have been prepared in accordance with the instructions for Form 10-Q and do not include all of the information and disclosures required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, all adjustments, consisting only of normal recurring adjustments considered necessary for a fair presentation, have been included. Operating results for any quarter are not necessarily indicative of the results for any other quarter or for the full year. These statements should be read in conjunction with the financial statements and notes to the financial statements thereto included in the Company&#8217;s Annual Report on Form 10-K for the year ended June 30, 2015.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><b>Recently Issued Accounting Guidance</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">In May 2014, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221; or &#8220;Update&#8221;) No. 2014-09, &#8220;Revenue from Contracts with Customers.&#8221; This ASU is a comprehensive new revenue recognition model that requires a company to recognize revenue to depict the transfer of goods or services to a customer at an amount that reflects the consideration it expects to receive in exchange for those goods or services. This ASU is effective for annual reporting periods beginning after December 15, 2016 and early adoption is not permitted. On July 9, 2015 the FASB voted to defer the effective date of this standard by one year to December 15, 2017 for the interim and annual reporting periods beginning after that date and permitted early adoption of the standard, but not before the original effective date of December 15, 2016. Companies may use either a full retrospective or modified retrospective approach to adopt this ASU. We are currently evaluating which transition approach to use and the full impact this ASU will have on our future financial statements.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">In August 2014, the FASB issued ASU No. 2014-15, to communicate amendments to FASB Account Standards Codification Subtopic 205-40, &#8220;Disclosure of Uncertainties about an Entity&#8217;s Ability to Continue as a Going Concern.&#8221; The ASU requires management to evaluate relevant conditions, events and certain management plans that are known or reasonably knowable as of the evaluation date when determining whether substantial doubt about an entity&#8217;s ability to continue as a going concern exists. Management will be required to make this evaluation for both annual and interim reporting periods. Management will have to make certain disclosures if it concludes that substantial doubt exists or when it plans to alleviate substantial doubt about the entity&#8217;s ability to continue as a going concern. The standard is effective for annual periods ending after December 15, 2016 and for interim reporting periods starting in 2017. Early adoption is permitted. We currently believe there will be no impact on our financial statement disclosures.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">In April 2015, the FASB issued ASU No. 2015-03, &#8220;Interest &#150; Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs&#8221;.&#160; This ASU requires companies to present debt issuance costs as a direct deduction from the carrying value of that debt liability. ASU 2015-03 does not impact the recognition and measurement guidance for debt issuance costs.&#160; This ASU was further amended by ASU No. 2015-15, &#8220;Interest-Imputation of Interest&#8221; to provide guidance with respect to debt issuance costs associated with line-of-credit arrangements. These ASUs are effective for annual reporting periods beginning after December 15, 2015 and early adoption is permitted. Accordingly, we will adopt this ASU on July 1, 2016.&#160; When implementing this ASU companies are required to use a retrospective approach and we are currently evaluating the impact to our future financial statements.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">In July 2015, the FASB issued ASU No. 2015-11 to simplify the subsequent measurement of inventory. Under this new standard, an entity should measure inventory at the lower of cost and net realizable value. Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2016. The amendments in this guidance should be applied prospectively with earlier application permitted as of the beginning of an interim or annual reporting period. The Company is currently evaluating the impact to our future financial statements.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px 0px 0px 0in; FONT: 10pt Times New Roman, Times, Serif" align="justify">In November 2015, the FASB issued ASU 2015-17, Balance Sheet Classification of Deferred Taxes (Topic 740). This update requires that entities with a classified balance sheet present all deferred tax assets and liabilities as noncurrent. This update is effective for annual and interim periods for fiscal years beginning after December 15, 2016, which will require us to adopt these provisions in the first quarter of fiscal 2018. Early adoption is permitted for financial statements that have not been previously issued. This update can be applied on either a prospective or retrospective basis. We do not expect the adoption of this update to have a material impact on our consolidated financial statements.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.4in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"> <b>Fair Value of Financial Instruments</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Company&#8217;s financial instruments consist of cash and cash equivalents, accounts receivable and accounts payable. The carrying amounts for cash and cash equivalents, accounts receivable and accounts payable approximate their fair value due to the short maturity of these instruments.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong>2. Inventories</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Inventories are comprised as follows:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>December&#160;31,&#160;2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>June&#160;30,&#160;2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Work-in progress</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>600,973</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>545,410</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Component parts</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>7,699,292</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>7,721,413</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Finished goods</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>2,264,931</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>2,397,044</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Reserve for obsolete and excess inventory</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>(1,466,952)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>(1,472,956)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>9,098,244</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>9,190,911</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"> Inventories are comprised as follows:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>December&#160;31,&#160;2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>June&#160;30,&#160;2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Work-in progress</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>600,973</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>545,410</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Component parts</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>7,699,292</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>7,721,413</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Finished goods</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>2,264,931</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>2,397,044</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Reserve for obsolete and excess inventory</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>(1,466,952)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>(1,472,956)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>9,098,244</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>9,190,911</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"> <b>3. Earnings per share</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Basic earnings per share are based on the weighted average number of shares of all common stock outstanding during the period. Diluted earnings per share are based on the sum of the weighted average number of shares of common stock and common stock equivalents outstanding during the period. The number of basic and diluted shares outstanding for the three and six months ended December 31, 2015 and 2014 were <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 8,027,147</font>.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><b>5. Financing</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">As of December 31, 2015, the Company is party to a Loan and Security Agreement, dated November 17, 2009, with Enterprise Bank &amp; Trust (the &#8220;Credit Agreement&#8221;) pursuant to which the Company obtained a secured revolving credit facility. Currently, the agreement provides for borrowing availability of up to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">5,000,000</font> (the &#8220;Credit Facility&#8221;). The Company&#8217;s obligations under the Credit Facility are secured by certain assets of the Company pursuant to the terms and subject to the conditions set forth in the Credit Agreement.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Credit Agreement was amended on November 9, 2015 extending the maturity date to November 9, 2016. Subject to the conditions and limitations set forth in the Credit Agreement, the Credit Facility will be available on a revolving basis until it expires on November 9, 2016, at which time all amounts outstanding under the Credit Facility will be due and payable. Advances under the Credit Facility will be made pursuant to a Revolving Credit Note (as defined in the Credit Agreement) executed by the Company in favor of Enterprise Bank &amp; Trust. Such advances will bear interest at a rate equal to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 3.50</font>% in excess of the 30-day LIBOR rate. Advances may be prepaid in whole or in part without premium or penalty.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"> While the Credit Agreement provides for stated availability of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">5.0</font> million, in connection with renewal on November 9, 2015, <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">a new covenant was added requiring the Company to maintain minimum &#8220;liquidity&#8221; of $1.25 million. Liquidity is defined as the difference between cash and cash equivalents and the aggregate principal balance of borrowings under the Credit Agreement and is measured at the last day of each fiscal quarter, commencing on December 31, 2015. Based on the Company&#8217;s cash and cash equivalents as of December 31,</font> the Company would only be permitted to borrow up to $.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">39</font> million as of such date. Decreases in the Company&#8217;s cash position will effectively reduce the amount the Company is able to borrow and/or require accelerated repayments.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"> Under the Credit Agreement, advances are generally subject to customary borrowing conditions.&#160;The Credit Agreement also contains covenants with which the Company must comply during the term of the Credit Facility. Among other things, such covenants restrict the Company&#8217;s ability to incur certain additional debt; make specified restricted payments, dividends and capital expenditures; authorize or issue capital stock; enter into certain transactions with affiliates; consolidate or merge with or acquire another business; sell certain of its assets or dissolve or wind up the Company. In addition, effective November 9, 2015, the Credit Agreement includes the minimum liquidity requirement described above. The Credit Agreement also contains certain events of default that are customary for financings of this type including, without limitation: the failure to pay principal, interest, fees or other amounts when due; the breach of specified representations or warranties contained in the loan documents; cross-default with certain other indebtedness of the Company; the entry of uninsured judgments that are not bonded or stayed; failure to comply with the observance or performance of specified agreements contained in the loan documents; commencement of bankruptcy or other insolvency proceedings; and the failure of any of the loan documents entered into in connection with the Credit Facility to be in full force and effect. After an event of default, and upon the continuation thereof, the principal amount of all loans made under the Credit Facility would bear interest at a rate per annum equal to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 4.00</font>% above the otherwise applicable interest rate (provided, that the interest rate may not exceed the highest rate permissible under law), and the lender would have the option to accelerate maturity and payment of the Company&#8217;s obligations under the Credit Facility.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"> The 30-day LIBOR rate was <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 0.42</font>% on December 31, 2015.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"> At December 31, 2015, the Company had no aggregate indebtedness, including capital lease obligations, short-term debt and long term debt.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; TEXT-INDENT: 0.75in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"> The Company was in compliance with all of the covenants associated with the Credit Facility at December 31, 2015.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> a new covenant was added requiring the Company to maintain minimum liquidity of $1.25 million. Liquidity is defined as the difference between cash and cash equivalents and the aggregate principal balance of borrowings under the Credit Agreement and is measured at the last day of each fiscal quarter, commencing on December 31, 2015. Based on the Companys cash and cash equivalents as of December 31, <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;BACKGROUND-COLOR: transparent; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><b>6. Income Taxes</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Company accounts for income taxes under ASC Topic 740: &#8220;Income Taxes.&#8221; Under ASC 740, the deferred tax provision is determined using the liability method, whereby deferred tax assets and liabilities are recognized based upon temporary differences between the financial statement and income tax bases of assets and liabilities using presently enacted tax rates. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized.&#160; In the three and six months ended December 31, 2015 the Company recorded the tax benefit of losses incurred in the amount of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">214,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">427,000</font>, respectively.&#160; As the realization of the tax benefit of the net operating loss is not assured, an additional valuation allowance of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">214,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">427,000</font>, net of the effect of the deferred taxes in the amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">44,000</font> and ($<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">45,000</font>), for the three and six months ended respectively, was also recorded. As a result of the expiration of tax benefits associated with expiring stock options not previously covered by the valuation allowance, the Company recorded a deferred tax benefit in the amount of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">124,000</font> for the three and six months ended respectively. For the three and six months ended December 31, 2014, the Company recorded the tax benefit of losses incurred in the amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">12,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">278,000</font> net of additions to the valuation allowance of like amounts.&#160; The total valuation allowance recorded by the Company as of December 31, 2015 and 2014 was approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,677,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,078,000</font>, respectively.&#160; To the extent that the Company&#8217;s losses continue in future quarters, the tax benefit of those losses will be subject to a valuation allowance.</div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> 214000 427000 214000 427000 0 124000 1677000 1078000 -21016 -9734 -39760 -20404 -0.09 -0.01 -0.15 -0.09 -0.09 -0.01 -0.15 -0.09 8027147 8027147 8027147 8027147 8027147 8027147 8027147 8027147 170000 170000 0.01 0.01 1500000 1500000 0 0 0 0 0.01 0.01 200000 200000 0 0 0 12000 278000 0 0.01 0.01 30000000 30000000 10427878 10427878 8027147 8027147 2400731 2400731 8027147 8027147 8027147 44000 45000 390000 <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"> <b>4. Commitments and Contingencies</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><b>Legal Claims</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.4in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px 0px 0px 0in; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Company is subject to various investigations, claims and legal proceedings covering a wide range of matters that arise in the ordinary course of its business activities. The Company intends to continue to conduct business in such a manner as to avert any FDA action seeking to interrupt or suspend manufacturing or require any recall or modification of products.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;BACKGROUND-COLOR: transparent; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;BACKGROUND-COLOR: transparent; TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Company has recognized the costs and associated liabilities only for those investigations, claims and legal proceedings for which, in its view, it is probable that liabilities have been incurred and the related amounts are estimable. Based upon information currently available, management believes that existing accrued liabilities are sufficient.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;BACKGROUND-COLOR: transparent; TEXT-INDENT: 0.4in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><u>Stuyvesant Falls Power Litigation</u>. The Company is currently involved in litigation with Niagara Mohawk Power Corporation d/b/a National Grid (&#8220;Niagara&#8221;) and other parties, which provides electrical power to the Company&#8217;s facility in Stuyvesant Falls, New York. In fiscal year 2011, Niagara began sending invoices to the Company for electricity used at the Company&#8217;s Stuyvesant Falls plant. The Company maintains in its defense of the lawsuit that it is entitled to a certain amount of free electricity based on covenants running with the land which have been honored for more than a century. Niagara&#8217;s attempts to collect such invoices were stopped in December 2010 by a temporary restraining order, although a court has not yet ruled on the merits of all of Niagara&#8217;s claims. Among other things, Niagara seeks as damages the value of electricity received by the Company without charge. While the total value of electricity at issue in the litigation is not known with certainty, Niagara alleges in its Motion For Summary Judgment, filed on March 14, 2014, damages of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">492,000</font> in free electricity since May 2010. Alternatively, Niagara asserts that, in the event that the free power covenant is still enforceable, the Company is still responsible for delivery fees relating to any free power to which it is entitled. The Company filed its own Motion For Summary Judgment on March 14, 2014, seeking dismissal of Niagara&#8217;s claims and oral arguments on the motions were held on June 13, 2014. On October 1, 2014, the Court granted the Company&#8217;s motion, denied Niagara&#8217;s motion and ruled that the Company is entitled to receive electrical power pursuant to the power covenants. On October 26 and October 30, 2014, Niagara and other parties filed separate notices of appeal of the Court&#8217;s decision. A settlement hearing occurred on March 19, 2015, but no settlement has been reached. The parties&#8217; respective appeal briefs have been filed and arguments occurred on February 11, 2016 before the Supreme Court of New York, Appellate Division, Third Department. As of December 31, 2015, the Company has not recorded a provision for this matter given management&#8217;s assessment of the probability of a loss.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; BACKGROUND-COLOR: transparent; TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"> <u>Dr&#228;ger Patent Litigation</u>. On or about October 4, 2013, Dr&#228;ger Medical GmbH and certain affiliates (the &#8220;Dr&#228;ger Plaintiffs&#8221;) filed a patent infringement lawsuit against the Company in the District of Delaware (the &#8220;2013 Dr&#228;ger Suit&#8221;), asserting that the Company infringes United States Patent Nos. 7,487,776 and 8,286,633 (the &#8220;&#8216;633 Patent&#8221;), both protecting particular combinations of carbon dioxide absorption cartridges and adapters which fit on anesthesia machines. The Dr&#228;ger Plaintiffs assert that the Company&#8217;s sales of certain models of its Litholyme and Carbolime single-use carbon dioxide absorption cartridges infringe both patents. The Company answered the Complaint, asserting invalidity of the patents, non-infringement, and implied license under the doctrine of permissive repair.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; BACKGROUND-COLOR: transparent; TEXT-INDENT: 0.4in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"> On October 25, 2013, the Dr&#228;ger Plaintiffs filed a motion for preliminary injunction requesting that the Company be enjoined from selling certain models of its Litholyme and Carbolime cartridges during the pendency of the litigation. A hearing on the motion for preliminary injunction was held on February 7, 2014. On March 24, 2014, the Court ruled in Allied&#8217;s favor and denied Dr&#228;ger&#8217;s motion for a preliminary injunction, stating among other things that Dr&#228;ger had not carried its burden of showing that Allied had infringed Dr&#228;ger&#8217;s patents. On June 20, 2014, the Company filed a motion seeking summary judgment based on the repair doctrine, which was the basis for the Court&#8217;s denial of Dr&#228;ger&#8217;s motion for preliminary injunction. On March 27, 2015, the Court granted the Company&#8217;s motion for summary judgment of non-infringement. The Dr&#228;ger Plaintiffs appealed the Court&#8217;s Order granting the motion for summary judgment on April 21, 2015 and briefs have been filed by both sides.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"> On October 13, 2015, the Dr&#228;ger Plaintiffs filed a new patent infringement lawsuit (the &#8220;2015 Dr&#228;ger Suit&#8221;) against the Company in the District of Delaware asserting that the Company infringes United States Reissue Patent No. RE45745, a reissue of the &#8216;633 Patent. The New Lawsuit alleged that the Company&#8217;s sales of the &#8220;Dr&#228;ger Style&#8221; models of its Litholyme and Carbolyme single-use carbon dioxide absorption cartridges infringe the claims of the reissued patent.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">On January 29, 2016, the Company and the Dr&#228;ger Plaintiffs resolved the 2013 Dr&#228;ger Suit and the 2015 Dr&#228;ger Suit pursuant to a mutually satisfactory settlement agreement. The appeal of the 2013 Dr&#228;ger Suit was dismissed on February 1, 2016 and the 2015 Dr&#228;ger Suit was resolved by a consent judgement and permanent injunction on February 12, 2016. The Company will not be required to make any payments under the settlement agreement, however, it discontinued the manufacture of Dr&#228;ger Style models of its Litholyme and Carbolyme single-use carbon dioxide absorption cartridges as of October 13, 2015. The Company does not believe that this settlement agreement will have a material effect on its business,&#160;financial position,&#160;results of operations or cash flows.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"> <b>Employment Contract</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 84pt; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Company has entered into an employment contract with its chief executive officer with annual renewals. The contract includes termination without cause and change of control provisions, under which the chief executive officer is entitled to receive specified severance payments generally equal to two times ending annual salary if the Company terminates his employment without cause or he voluntarily terminates his employment with &#8220;good reason.&#8221; &#8220;Good Reason&#8221; generally includes changes in the scope of his duties or location of employment but also includes (i) the Company&#8217;s written election not to renew the Employment Agreement and (ii) certain voluntary resignations by the chief executive officer following a &#8220;Change of Control&#8221; as defined in the Agreement.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> EX-101.SCH 7 ahpi-20151231.xsd XBRL TAXONOMY EXTENSION SCHEMA 101 - Document - Document And Entity Information link:presentationLink link:definitionLink link:calculationLink 102 - Statement - STATEMENT OF OPERATIONS link:presentationLink link:definitionLink link:calculationLink 103 - Statement - BALANCE SHEET link:presentationLink link:definitionLink link:calculationLink 104 - Statement - BALANCE SHEET [Parenthetical] link:presentationLink link:definitionLink link:calculationLink 105 - Statement - STATEMENT OF CASH FLOWS link:presentationLink link:definitionLink link:calculationLink 106 - Disclosure - Summary of Significant Accounting and Reporting Policies link:presentationLink link:definitionLink link:calculationLink 107 - Disclosure - Inventories link:presentationLink link:definitionLink link:calculationLink 108 - Disclosure - Earnings per share link:presentationLink link:definitionLink link:calculationLink 109 - Disclosure - Commitments and Contingencies link:presentationLink link:definitionLink link:calculationLink 110 - Disclosure - Financing link:presentationLink link:definitionLink link:calculationLink 111 - Disclosure - Income Taxes link:presentationLink link:definitionLink link:calculationLink 112 - Disclosure - Summary of Significant Accounting and Reporting Policies (Policies) link:presentationLink link:definitionLink link:calculationLink 113 - Disclosure - Inventories (Tables) link:presentationLink link:definitionLink link:calculationLink 114 - Disclosure - Inventories (Details) link:presentationLink link:definitionLink link:calculationLink 115 - Disclosure - Earnings per share (Details Textual) link:presentationLink link:definitionLink link:calculationLink 116 - Disclosure - Commitments and Contingencies (Details Textual) link:presentationLink link:definitionLink link:calculationLink 117 - Disclosure - Financing (Details Textual) link:presentationLink link:definitionLink link:calculationLink 118 - Disclosure - Income Taxes (Details Textual) link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 8 ahpi-20151231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 9 ahpi-20151231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 10 ahpi-20151231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE EX-101.PRE 11 ahpi-20151231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 12 R1.htm IDEA: XBRL DOCUMENT v3.3.1.900
Document And Entity Information - shares
 6 Months Ended
Dec. 31, 2015
Jan. 30, 2016
Document Information [Line Items]    
Document Type 10-Q  
Amendment Flag false  
Document Period End Date Dec. 31, 2015  
Document Fiscal Year Focus 2016  
Document Fiscal Period Focus Q2  
Entity Registrant Name ALLIED HEALTHCARE PRODUCTS INC  
Entity Central Index Key 0000874710  
Current Fiscal Year End Date --06-30  
Entity Filer Category Smaller Reporting Company  
Trading Symbol AHPI  
Entity Common Stock, Shares Outstanding   8,027,147
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.3.1.900
STATEMENT OF OPERATIONS - USD ($)
 3 Months Ended 6 Months Ended
Dec. 31, 2015
Dec. 31, 2014
Dec. 31, 2015
Dec. 31, 2014
Net sales $ 8,846,359 $ 8,999,662 $ 17,309,196 $ 17,844,929
Cost of sales 7,067,748 6,841,177 13,832,294 14,111,661
Gross profit 1,778,611 2,158,485 3,476,902 3,733,268
Selling, general and administrative expenses 2,466,359 2,193,501 4,799,371 4,465,789
Loss from operations (687,748) (35,016) (1,322,469) (732,521)
Other (income) expenses:        
Interest income (838) (799) (1,902) (1,554)
Other, net 21,854 10,533 41,662 21,958
Nonoperating Income (Expense) 21,016 9,734 39,760 20,404
Loss before benefit from income taxes (708,764) (44,750) (1,362,229) (752,925)
Benefit from income taxes 0 0 (123,907) 0
Net loss $ (708,764) $ (44,750) $ (1,238,322) $ (752,925)
Basic loss per share (in dollars per share) $ (0.09) $ (0.01) $ (0.15) $ (0.09)
Diluted loss per share (in dollars per share) $ (0.09) $ (0.01) $ (0.15) $ (0.09)
Weighted average shares outstanding - basic (in shares) 8,027,147 8,027,147 8,027,147 8,027,147
Weighted average shares outstanding - diluted (in shares) 8,027,147 8,027,147 8,027,147 8,027,147
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.3.1.900
BALANCE SHEET - USD ($)
Dec. 31, 2015
Jun. 30, 2015
Current assets:    
Cash and cash equivalents $ 1,638,462 $ 2,039,946
Accounts receivable, net of allowances of $170,000 3,722,126 3,574,674
Inventories, net 9,098,244 9,190,911
Income tax receivable 22,262 12,487
Other current assets 352,682 328,756
Total current assets 14,833,776 15,146,774
Property, plant and equipment, net 7,316,436 7,821,206
Deferred income taxes 1,922,095 1,889,872
Other assets, net 103,839 131,615
Total assets 24,176,146 24,989,467
Current liabilities:    
Accounts payable 1,973,083 1,368,797
Other accrued liabilities 2,070,178 2,159,566
Deferred income taxes 795,079 767,907
Total current liabilities $ 4,838,340 $ 4,296,270
Commitments and contingencies
Stockholders' equity:    
Preferred stock $ 0 $ 0
Common stock; $0.01 par value; 30,000,000 shares authorized; 10,427,878 shares issued at December 31, 2015 and June 30, 2015; 8,027,147 shares outstanding at December 31, 2015 and June 30, 2015 104,279 104,279
Additional paid-in capital 48,429,601 48,546,670
Accumulated deficit (8,215,286) (6,976,964)
Less treasury stock, at cost; 2,400,731 shares at December 31, 2015 and June 30, 2015, respectively (20,980,788) (20,980,788)
Total stockholders' equity 19,337,806 20,693,197
Total liabilities and stockholders' equity 24,176,146 24,989,467
Series A Preferred Stock [Member]    
Stockholders' equity:    
Preferred stock $ 0 $ 0
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.3.1.900
BALANCE SHEET [Parenthetical] - USD ($)
Dec. 31, 2015
Jun. 30, 2015
Allowances for accounts receivable (in dollars) $ 170,000 $ 170,000
Preferred stock, par value (in dollars per share) $ 0.01 $ 0.01
Preferred stock, shares authorized 1,500,000 1,500,000
Preferred stock, shares issued 0 0
Preferred stock, shares outstanding 0 0
Common stock, par value (in dollars per share) $ 0.01 $ 0.01
Common stock, shares authorized 30,000,000 30,000,000
Common stock, shares issued 10,427,878 10,427,878
Common stock, shares outstanding 8,027,147 8,027,147
Treasury stock, at cost 2,400,731 2,400,731
Series A Preferred Stock [Member]    
Preferred stock, par value (in dollars per share) $ 0.01 $ 0.01
Preferred stock, shares authorized 200,000 200,000
Preferred stock, shares issued 0 0
Preferred stock, shares outstanding 0 0
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.3.1.900
STATEMENT OF CASH FLOWS - USD ($)
 6 Months Ended
Dec. 31, 2015
Dec. 31, 2014
Cash flows from operating activities:    
Net loss $ (1,238,322) $ (752,925)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:    
Depreciation and amortization 631,844 667,127
Stock based compensation 1,788 2,853
Provision for doubtful accounts and sales returns and allowances 2,860 27,838
Deferred taxes (123,907) 0
Changes in operating assets and liabilities:    
Accounts receivable (150,311) 415,105
Inventories 92,667 (213,351)
Income tax receivable (9,775) (10,424)
Other current assets (23,926) (140,094)
Accounts payable 604,287 138,995
Other accrued liabilities (89,389) 123,055
Net cash provided by (used in) operating activities (302,184) 258,179
Cash flows from investing activities:    
Capital expenditures (99,300) (86,088)
Net cash used in investing activities (99,300) (86,088)
Net increase (decrease) in cash and cash equivalents (401,484) 172,091
Cash and cash equivalents at beginning of period 2,039,946 1,366,762
Cash and cash equivalents at end of period $ 1,638,462 $ 1,538,853
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.3.1.900
Summary of Significant Accounting and Reporting Policies
 6 Months Ended
Dec. 31, 2015
Accounting Policies [Abstract]  
Significant Accounting Policies [Text Block]
1. Summary of Significant Accounting and Reporting Policies
 
Basis of Presentation
 
The accompanying unaudited financial statements of Allied Healthcare Products, Inc. (the “Company”) have been prepared in accordance with the instructions for Form 10-Q and do not include all of the information and disclosures required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, all adjustments, consisting only of normal recurring adjustments considered necessary for a fair presentation, have been included. Operating results for any quarter are not necessarily indicative of the results for any other quarter or for the full year. These statements should be read in conjunction with the financial statements and notes to the financial statements thereto included in the Company’s Annual Report on Form 10-K for the year ended June 30, 2015.
 
Recently Issued Accounting Guidance
 
In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU” or “Update”) No. 2014-09, “Revenue from Contracts with Customers.” This ASU is a comprehensive new revenue recognition model that requires a company to recognize revenue to depict the transfer of goods or services to a customer at an amount that reflects the consideration it expects to receive in exchange for those goods or services. This ASU is effective for annual reporting periods beginning after December 15, 2016 and early adoption is not permitted. On July 9, 2015 the FASB voted to defer the effective date of this standard by one year to December 15, 2017 for the interim and annual reporting periods beginning after that date and permitted early adoption of the standard, but not before the original effective date of December 15, 2016. Companies may use either a full retrospective or modified retrospective approach to adopt this ASU. We are currently evaluating which transition approach to use and the full impact this ASU will have on our future financial statements.
 
In August 2014, the FASB issued ASU No. 2014-15, to communicate amendments to FASB Account Standards Codification Subtopic 205-40, “Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern.” The ASU requires management to evaluate relevant conditions, events and certain management plans that are known or reasonably knowable as of the evaluation date when determining whether substantial doubt about an entity’s ability to continue as a going concern exists. Management will be required to make this evaluation for both annual and interim reporting periods. Management will have to make certain disclosures if it concludes that substantial doubt exists or when it plans to alleviate substantial doubt about the entity’s ability to continue as a going concern. The standard is effective for annual periods ending after December 15, 2016 and for interim reporting periods starting in 2017. Early adoption is permitted. We currently believe there will be no impact on our financial statement disclosures.
 
In April 2015, the FASB issued ASU No. 2015-03, “Interest – Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs”.  This ASU requires companies to present debt issuance costs as a direct deduction from the carrying value of that debt liability. ASU 2015-03 does not impact the recognition and measurement guidance for debt issuance costs.  This ASU was further amended by ASU No. 2015-15, “Interest-Imputation of Interest” to provide guidance with respect to debt issuance costs associated with line-of-credit arrangements. These ASUs are effective for annual reporting periods beginning after December 15, 2015 and early adoption is permitted. Accordingly, we will adopt this ASU on July 1, 2016.  When implementing this ASU companies are required to use a retrospective approach and we are currently evaluating the impact to our future financial statements.
 
In July 2015, the FASB issued ASU No. 2015-11 to simplify the subsequent measurement of inventory. Under this new standard, an entity should measure inventory at the lower of cost and net realizable value. Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2016. The amendments in this guidance should be applied prospectively with earlier application permitted as of the beginning of an interim or annual reporting period. The Company is currently evaluating the impact to our future financial statements.
 
In November 2015, the FASB issued ASU 2015-17, Balance Sheet Classification of Deferred Taxes (Topic 740). This update requires that entities with a classified balance sheet present all deferred tax assets and liabilities as noncurrent. This update is effective for annual and interim periods for fiscal years beginning after December 15, 2016, which will require us to adopt these provisions in the first quarter of fiscal 2018. Early adoption is permitted for financial statements that have not been previously issued. This update can be applied on either a prospective or retrospective basis. We do not expect the adoption of this update to have a material impact on our consolidated financial statements.
 
Fair Value of Financial Instruments
 
The Company’s financial instruments consist of cash and cash equivalents, accounts receivable and accounts payable. The carrying amounts for cash and cash equivalents, accounts receivable and accounts payable approximate their fair value due to the short maturity of these instruments.
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.3.1.900
Inventories
 6 Months Ended
Dec. 31, 2015
Inventory, Net [Abstract]  
Inventory Disclosure [Text Block]
2. Inventories
 
Inventories are comprised as follows:
 
 
 
December 31, 2015
 
June 30, 2015
 
 
 
 
 
 
 
 
 
Work-in progress
 
$
600,973
 
$
545,410
 
Component parts
 
 
7,699,292
 
 
7,721,413
 
Finished goods
 
 
2,264,931
 
 
2,397,044
 
Reserve for obsolete and excess inventory
 
 
(1,466,952)
 
 
(1,472,956)
 
 
 
$
9,098,244
 
$
9,190,911
 
XML 19 R8.htm IDEA: XBRL DOCUMENT v3.3.1.900
Earnings per share
 6 Months Ended
Dec. 31, 2015
Earnings Per Share [Abstract]  
Earnings Per Share [Text Block]
3. Earnings per share
 
Basic earnings per share are based on the weighted average number of shares of all common stock outstanding during the period. Diluted earnings per share are based on the sum of the weighted average number of shares of common stock and common stock equivalents outstanding during the period. The number of basic and diluted shares outstanding for the three and six months ended December 31, 2015 and 2014 were 8,027,147.
XML 20 R9.htm IDEA: XBRL DOCUMENT v3.3.1.900
Commitments and Contingencies
 6 Months Ended
Dec. 31, 2015
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies Disclosure [Text Block]
4. Commitments and Contingencies
 
Legal Claims
 
The Company is subject to various investigations, claims and legal proceedings covering a wide range of matters that arise in the ordinary course of its business activities. The Company intends to continue to conduct business in such a manner as to avert any FDA action seeking to interrupt or suspend manufacturing or require any recall or modification of products.
 
The Company has recognized the costs and associated liabilities only for those investigations, claims and legal proceedings for which, in its view, it is probable that liabilities have been incurred and the related amounts are estimable. Based upon information currently available, management believes that existing accrued liabilities are sufficient.
 
Stuyvesant Falls Power Litigation. The Company is currently involved in litigation with Niagara Mohawk Power Corporation d/b/a National Grid (“Niagara”) and other parties, which provides electrical power to the Company’s facility in Stuyvesant Falls, New York. In fiscal year 2011, Niagara began sending invoices to the Company for electricity used at the Company’s Stuyvesant Falls plant. The Company maintains in its defense of the lawsuit that it is entitled to a certain amount of free electricity based on covenants running with the land which have been honored for more than a century. Niagara’s attempts to collect such invoices were stopped in December 2010 by a temporary restraining order, although a court has not yet ruled on the merits of all of Niagara’s claims. Among other things, Niagara seeks as damages the value of electricity received by the Company without charge. While the total value of electricity at issue in the litigation is not known with certainty, Niagara alleges in its Motion For Summary Judgment, filed on March 14, 2014, damages of approximately $492,000 in free electricity since May 2010. Alternatively, Niagara asserts that, in the event that the free power covenant is still enforceable, the Company is still responsible for delivery fees relating to any free power to which it is entitled. The Company filed its own Motion For Summary Judgment on March 14, 2014, seeking dismissal of Niagara’s claims and oral arguments on the motions were held on June 13, 2014. On October 1, 2014, the Court granted the Company’s motion, denied Niagara’s motion and ruled that the Company is entitled to receive electrical power pursuant to the power covenants. On October 26 and October 30, 2014, Niagara and other parties filed separate notices of appeal of the Court’s decision. A settlement hearing occurred on March 19, 2015, but no settlement has been reached. The parties’ respective appeal briefs have been filed and arguments occurred on February 11, 2016 before the Supreme Court of New York, Appellate Division, Third Department. As of December 31, 2015, the Company has not recorded a provision for this matter given management’s assessment of the probability of a loss.
 
Dräger Patent Litigation. On or about October 4, 2013, Dräger Medical GmbH and certain affiliates (the “Dräger Plaintiffs”) filed a patent infringement lawsuit against the Company in the District of Delaware (the “2013 Dräger Suit”), asserting that the Company infringes United States Patent Nos. 7,487,776 and 8,286,633 (the “‘633 Patent”), both protecting particular combinations of carbon dioxide absorption cartridges and adapters which fit on anesthesia machines. The Dräger Plaintiffs assert that the Company’s sales of certain models of its Litholyme and Carbolime single-use carbon dioxide absorption cartridges infringe both patents. The Company answered the Complaint, asserting invalidity of the patents, non-infringement, and implied license under the doctrine of permissive repair.
 
On October 25, 2013, the Dräger Plaintiffs filed a motion for preliminary injunction requesting that the Company be enjoined from selling certain models of its Litholyme and Carbolime cartridges during the pendency of the litigation. A hearing on the motion for preliminary injunction was held on February 7, 2014. On March 24, 2014, the Court ruled in Allied’s favor and denied Dräger’s motion for a preliminary injunction, stating among other things that Dräger had not carried its burden of showing that Allied had infringed Dräger’s patents. On June 20, 2014, the Company filed a motion seeking summary judgment based on the repair doctrine, which was the basis for the Court’s denial of Dräger’s motion for preliminary injunction. On March 27, 2015, the Court granted the Company’s motion for summary judgment of non-infringement. The Dräger Plaintiffs appealed the Court’s Order granting the motion for summary judgment on April 21, 2015 and briefs have been filed by both sides.
 
On October 13, 2015, the Dräger Plaintiffs filed a new patent infringement lawsuit (the “2015 Dräger Suit”) against the Company in the District of Delaware asserting that the Company infringes United States Reissue Patent No. RE45745, a reissue of the ‘633 Patent. The New Lawsuit alleged that the Company’s sales of the “Dräger Style” models of its Litholyme and Carbolyme single-use carbon dioxide absorption cartridges infringe the claims of the reissued patent.
 
On January 29, 2016, the Company and the Dräger Plaintiffs resolved the 2013 Dräger Suit and the 2015 Dräger Suit pursuant to a mutually satisfactory settlement agreement. The appeal of the 2013 Dräger Suit was dismissed on February 1, 2016 and the 2015 Dräger Suit was resolved by a consent judgement and permanent injunction on February 12, 2016. The Company will not be required to make any payments under the settlement agreement, however, it discontinued the manufacture of Dräger Style models of its Litholyme and Carbolyme single-use carbon dioxide absorption cartridges as of October 13, 2015. The Company does not believe that this settlement agreement will have a material effect on its business, financial position, results of operations or cash flows.
 
Employment Contract
 
The Company has entered into an employment contract with its chief executive officer with annual renewals. The contract includes termination without cause and change of control provisions, under which the chief executive officer is entitled to receive specified severance payments generally equal to two times ending annual salary if the Company terminates his employment without cause or he voluntarily terminates his employment with “good reason.” “Good Reason” generally includes changes in the scope of his duties or location of employment but also includes (i) the Company’s written election not to renew the Employment Agreement and (ii) certain voluntary resignations by the chief executive officer following a “Change of Control” as defined in the Agreement.
XML 21 R10.htm IDEA: XBRL DOCUMENT v3.3.1.900
Financing
 6 Months Ended
Dec. 31, 2015
Debt Disclosure [Abstract]  
Debt Disclosure [Text Block]
5. Financing
 
As of December 31, 2015, the Company is party to a Loan and Security Agreement, dated November 17, 2009, with Enterprise Bank & Trust (the “Credit Agreement”) pursuant to which the Company obtained a secured revolving credit facility. Currently, the agreement provides for borrowing availability of up to $5,000,000 (the “Credit Facility”). The Company’s obligations under the Credit Facility are secured by certain assets of the Company pursuant to the terms and subject to the conditions set forth in the Credit Agreement.
 
The Credit Agreement was amended on November 9, 2015 extending the maturity date to November 9, 2016. Subject to the conditions and limitations set forth in the Credit Agreement, the Credit Facility will be available on a revolving basis until it expires on November 9, 2016, at which time all amounts outstanding under the Credit Facility will be due and payable. Advances under the Credit Facility will be made pursuant to a Revolving Credit Note (as defined in the Credit Agreement) executed by the Company in favor of Enterprise Bank & Trust. Such advances will bear interest at a rate equal to 3.50% in excess of the 30-day LIBOR rate. Advances may be prepaid in whole or in part without premium or penalty.
 
While the Credit Agreement provides for stated availability of $5.0 million, in connection with renewal on November 9, 2015, a new covenant was added requiring the Company to maintain minimum “liquidity” of $1.25 million. Liquidity is defined as the difference between cash and cash equivalents and the aggregate principal balance of borrowings under the Credit Agreement and is measured at the last day of each fiscal quarter, commencing on December 31, 2015. Based on the Company’s cash and cash equivalents as of December 31, the Company would only be permitted to borrow up to $.39 million as of such date. Decreases in the Company’s cash position will effectively reduce the amount the Company is able to borrow and/or require accelerated repayments.
 
Under the Credit Agreement, advances are generally subject to customary borrowing conditions. The Credit Agreement also contains covenants with which the Company must comply during the term of the Credit Facility. Among other things, such covenants restrict the Company’s ability to incur certain additional debt; make specified restricted payments, dividends and capital expenditures; authorize or issue capital stock; enter into certain transactions with affiliates; consolidate or merge with or acquire another business; sell certain of its assets or dissolve or wind up the Company. In addition, effective November 9, 2015, the Credit Agreement includes the minimum liquidity requirement described above. The Credit Agreement also contains certain events of default that are customary for financings of this type including, without limitation: the failure to pay principal, interest, fees or other amounts when due; the breach of specified representations or warranties contained in the loan documents; cross-default with certain other indebtedness of the Company; the entry of uninsured judgments that are not bonded or stayed; failure to comply with the observance or performance of specified agreements contained in the loan documents; commencement of bankruptcy or other insolvency proceedings; and the failure of any of the loan documents entered into in connection with the Credit Facility to be in full force and effect. After an event of default, and upon the continuation thereof, the principal amount of all loans made under the Credit Facility would bear interest at a rate per annum equal to 4.00% above the otherwise applicable interest rate (provided, that the interest rate may not exceed the highest rate permissible under law), and the lender would have the option to accelerate maturity and payment of the Company’s obligations under the Credit Facility.
 
The 30-day LIBOR rate was 0.42% on December 31, 2015.
 
At December 31, 2015, the Company had no aggregate indebtedness, including capital lease obligations, short-term debt and long term debt.
 
The Company was in compliance with all of the covenants associated with the Credit Facility at December 31, 2015.
XML 22 R11.htm IDEA: XBRL DOCUMENT v3.3.1.900
Income Taxes
 6 Months Ended
Dec. 31, 2015
Income Tax Disclosure [Abstract]  
Income Tax Disclosure [Text Block]
6. Income Taxes
 
The Company accounts for income taxes under ASC Topic 740: “Income Taxes.” Under ASC 740, the deferred tax provision is determined using the liability method, whereby deferred tax assets and liabilities are recognized based upon temporary differences between the financial statement and income tax bases of assets and liabilities using presently enacted tax rates. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized.  In the three and six months ended December 31, 2015 the Company recorded the tax benefit of losses incurred in the amount of approximately $214,000 and $427,000, respectively.  As the realization of the tax benefit of the net operating loss is not assured, an additional valuation allowance of approximately $214,000 and $427,000, net of the effect of the deferred taxes in the amount of $44,000 and ($45,000), for the three and six months ended respectively, was also recorded. As a result of the expiration of tax benefits associated with expiring stock options not previously covered by the valuation allowance, the Company recorded a deferred tax benefit in the amount of approximately $0 and $124,000 for the three and six months ended respectively. For the three and six months ended December 31, 2014, the Company recorded the tax benefit of losses incurred in the amount of $12,000 and $278,000 net of additions to the valuation allowance of like amounts.  The total valuation allowance recorded by the Company as of December 31, 2015 and 2014 was approximately $1,677,000 and $1,078,000, respectively.  To the extent that the Company’s losses continue in future quarters, the tax benefit of those losses will be subject to a valuation allowance.
XML 23 R12.htm IDEA: XBRL DOCUMENT v3.3.1.900
Summary of Significant Accounting and Reporting Policies (Policies)
 6 Months Ended
Dec. 31, 2015
Accounting Policies [Abstract]  
Basis of Accounting, Policy [Policy Text Block]
Basis of Presentation
 
The accompanying unaudited financial statements of Allied Healthcare Products, Inc. (the “Company”) have been prepared in accordance with the instructions for Form 10-Q and do not include all of the information and disclosures required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, all adjustments, consisting only of normal recurring adjustments considered necessary for a fair presentation, have been included. Operating results for any quarter are not necessarily indicative of the results for any other quarter or for the full year. These statements should be read in conjunction with the financial statements and notes to the financial statements thereto included in the Company’s Annual Report on Form 10-K for the year ended June 30, 2015.
New Accounting Pronouncements, Policy [Policy Text Block]
Recently Issued Accounting Guidance
 
In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU” or “Update”) No. 2014-09, “Revenue from Contracts with Customers.” This ASU is a comprehensive new revenue recognition model that requires a company to recognize revenue to depict the transfer of goods or services to a customer at an amount that reflects the consideration it expects to receive in exchange for those goods or services. This ASU is effective for annual reporting periods beginning after December 15, 2016 and early adoption is not permitted. On July 9, 2015 the FASB voted to defer the effective date of this standard by one year to December 15, 2017 for the interim and annual reporting periods beginning after that date and permitted early adoption of the standard, but not before the original effective date of December 15, 2016. Companies may use either a full retrospective or modified retrospective approach to adopt this ASU. We are currently evaluating which transition approach to use and the full impact this ASU will have on our future financial statements.
 
In August 2014, the FASB issued ASU No. 2014-15, to communicate amendments to FASB Account Standards Codification Subtopic 205-40, “Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern.” The ASU requires management to evaluate relevant conditions, events and certain management plans that are known or reasonably knowable as of the evaluation date when determining whether substantial doubt about an entity’s ability to continue as a going concern exists. Management will be required to make this evaluation for both annual and interim reporting periods. Management will have to make certain disclosures if it concludes that substantial doubt exists or when it plans to alleviate substantial doubt about the entity’s ability to continue as a going concern. The standard is effective for annual periods ending after December 15, 2016 and for interim reporting periods starting in 2017. Early adoption is permitted. We currently believe there will be no impact on our financial statement disclosures.
 
In April 2015, the FASB issued ASU No. 2015-03, “Interest – Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs”.  This ASU requires companies to present debt issuance costs as a direct deduction from the carrying value of that debt liability. ASU 2015-03 does not impact the recognition and measurement guidance for debt issuance costs.  This ASU was further amended by ASU No. 2015-15, “Interest-Imputation of Interest” to provide guidance with respect to debt issuance costs associated with line-of-credit arrangements. These ASUs are effective for annual reporting periods beginning after December 15, 2015 and early adoption is permitted. Accordingly, we will adopt this ASU on July 1, 2016.  When implementing this ASU companies are required to use a retrospective approach and we are currently evaluating the impact to our future financial statements.
 
In July 2015, the FASB issued ASU No. 2015-11 to simplify the subsequent measurement of inventory. Under this new standard, an entity should measure inventory at the lower of cost and net realizable value. Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2016. The amendments in this guidance should be applied prospectively with earlier application permitted as of the beginning of an interim or annual reporting period. The Company is currently evaluating the impact to our future financial statements.
 
In November 2015, the FASB issued ASU 2015-17, Balance Sheet Classification of Deferred Taxes (Topic 740). This update requires that entities with a classified balance sheet present all deferred tax assets and liabilities as noncurrent. This update is effective for annual and interim periods for fiscal years beginning after December 15, 2016, which will require us to adopt these provisions in the first quarter of fiscal 2018. Early adoption is permitted for financial statements that have not been previously issued. This update can be applied on either a prospective or retrospective basis. We do not expect the adoption of this update to have a material impact on our consolidated financial statements.
Fair Value of Financial Instruments, Policy [Policy Text Block]
Fair Value of Financial Instruments
 
The Company’s financial instruments consist of cash and cash equivalents, accounts receivable and accounts payable. The carrying amounts for cash and cash equivalents, accounts receivable and accounts payable approximate their fair value due to the short maturity of these instruments.
XML 24 R13.htm IDEA: XBRL DOCUMENT v3.3.1.900
Inventories (Tables)
 6 Months Ended
Dec. 31, 2015
Inventory, Net [Abstract]  
Schedule of Inventory, Current [Table Text Block]
Inventories are comprised as follows:
 
 
 
December 31, 2015
 
June 30, 2015
 
 
 
 
 
 
 
 
 
Work-in progress
 
$
600,973
 
$
545,410
 
Component parts
 
 
7,699,292
 
 
7,721,413
 
Finished goods
 
 
2,264,931
 
 
2,397,044
 
Reserve for obsolete and excess inventory
 
 
(1,466,952)
 
 
(1,472,956)
 
 
 
$
9,098,244
 
$
9,190,911
 
XML 25 R14.htm IDEA: XBRL DOCUMENT v3.3.1.900
Inventories (Details) - USD ($)
Dec. 31, 2015
Jun. 30, 2015
Inventory [Line Items]    
Work-in progress $ 600,973 $ 545,410
Component parts 7,699,292 7,721,413
Finished goods 2,264,931 2,397,044
Reserve for obsolete and excess inventory (1,466,952) (1,472,956)
Inventory, Net $ 9,098,244 $ 9,190,911
XML 26 R15.htm IDEA: XBRL DOCUMENT v3.3.1.900
Earnings per share (Details Textual) - shares
 3 Months Ended 6 Months Ended
Dec. 31, 2015
Dec. 31, 2014
Dec. 31, 2015
Dec. 31, 2014
Earnings Per Share [Line Items]        
Weighted Average Number of Shares Outstanding, Basic and Diluted 8,027,147 8,027,147 8,027,147 8,027,147
XML 27 R16.htm IDEA: XBRL DOCUMENT v3.3.1.900
Commitments and Contingencies (Details Textual)
Mar. 14, 2014
USD ($)
Niagara [Member]  
Commitments and Contingencies [Line Items]  
Loss Contingency, Damages Sought, Value $ 492,000
XML 28 R17.htm IDEA: XBRL DOCUMENT v3.3.1.900
Financing (Details Textual) - USD ($)
 6 Months Ended
Nov. 09, 2015
Dec. 31, 2015
Nov. 17, 2009
Debt Instrument [Line Items]      
Line Of Credit Facility, Maximum Borrowing Capacity $ 5,000,000   $ 5,000,000
Line of Credit Facility, Current Borrowing Capacity $ 390,000    
Debt Instrument, Interest Rate, Stated Percentage Rate Range, Minimum   3.50%  
Debt Instrument, Interest Rate, Stated Percentage   4.00%  
Debt Instrument, Basis Spread on Variable Rate   0.42%  
Line of Credit Facility, Covenant Terms a new covenant was added requiring the Company to maintain minimum liquidity of $1.25 million. Liquidity is defined as the difference between cash and cash equivalents and the aggregate principal balance of borrowings under the Credit Agreement and is measured at the last day of each fiscal quarter, commencing on December 31, 2015. Based on the Companys cash and cash equivalents as of December 31,    
XML 29 R18.htm IDEA: XBRL DOCUMENT v3.3.1.900
Income Taxes (Details Textual) - USD ($)
 3 Months Ended 6 Months Ended
Dec. 31, 2015
Dec. 31, 2014
Dec. 31, 2015
Dec. 31, 2014
Schedule Of Income Tax Disclosure [Line Items]        
Deferred Other Tax Expense (Benefit) $ 214,000   $ 427,000  
Deferred Tax Assets Valuation Allowance Addition Amount 214,000   427,000  
Deferred Tax Assets, Valuation Allowance 1,677,000 $ 1,078,000 1,677,000 $ 1,078,000
Excess Tax Benefit From Shares Based Compensation Operating Activities 0   124,000  
Current Income Tax Expense (Benefit), Total   $ 12,000   $ 278,000
Deferred Income Tax Expense Benefits $ 44,000   $ 45,000  
EXCEL 30 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( #Q@4$BO2Y&W?@$ /L- 3 6T-O;G1E;G1?5'EP97-= M+GAM;,U7RV[",!#\%91K18QI2Q\"+J77%JG] 3?9$ N_9)L ?U\[0-5&*8*6 M2'N)X\SNSMAKCY3Q^]: ZVVD4&Z2E-Z;1T)<5H)D+M4&5$ *;27S86H7Q+!L MR19 AH/!B&1:>5"^[V.-9#I^K0Z6\F0DOI #550]XW-@1: MSUM.20B>!]214/I?W(>3DFD+)Q'&P XO1AOZVWXWO =WIB'VMWW]K M>@TZ4@\=FL19.H9(=%PCT7,[% M *P( L !?.0Q(OW[CMB PD.MQ-*O>X^NO ZIK XTHO8<4M?'5$Q^#*G*_=IT MJK$"2+8CCVG!D4*>-BP>-9?20D0[8$NP+,L5R*V.V:SGVL7.U49V[M,41Y26 MM#;3"&>6X9MY6&3I//B)]!=C;IK>TI;MR5/0!_ZS#0//>997'L=V+YRO+0O] MC^AY%.!)T:'B1?4C9@,2[2F]@OIZ (4QOCLEFI2"(S>C@KN_V/P"4$L#!!0 M ( #Q@4$@_48L;+0$ %,, : >&PO7W)E;',O=V]R:V)O;VLN>&UL M+G)E;'/%UTMN@S 0@.&K(!\@9DA"$A2RRB;;MA>P8'@H8"/;59O;UV51T8=' M72#-!@269K[5+SAKEQ9/."C?&^VZ?G+)^SAH5X3WI>B\GPHI7=7AJ-S&3*C# M:6/LJ'QXM*V<5'57+C+V[#M$[ M.=]@$Q:$X\>$_UEOFJ:O\&JJUQ&U_T,AOQ8(&0=E<5#& MK&05L6T"X.VK& M]G'0G@64QT$Y"^@0!QU80,6@.1:^#I-1#! M!IYB Y%LX&DV$-$&GFH#D6W@Z380X0:><@.1;N!I-RSB[3IEL7[VMM>M6UOS M;3CY$;F(M_./ =>GS%-)PZ+6/FQ".5]7[_0\]1,B?_T_7#X 4$L#!!0 ( M #Q@4$A53JL?,P( 'P& 0 9&]C4')O<',O87!P+GAM;+U536_;, S] M*X)/W6%U$@Q#$:0&/,=! J1-,'OML6!E.A%J2X:D!,E^_6B[<>WF"]MA/E'D M(ZGW*,(C:7K#I58%:BO0L%V>23,DY[VSMK88NJ[A:\S!W!)$4C15.@=+1[UR M59H*CF/%-SE*ZPYZO>\N[BS*!).O15/4\49E%[\H,L'!"B6]!\&U,BJU+-QQ MS$;N9T"5094CY!LM[-[KU9BVJ\)$'#(,J)>70F:P1GTX*TR@\@+DWJU/-#B";4IF?8' MMSWZ&@D._KHV0B+D:@E"&V^TM<,M#MT\Q70_X[!7,%B: M]\X6M !I'6;$;SH.G+IM[:WLK#!6>\]*OYDUHC4CMW%69AO;ML4WKW]7(*W9S6:U.>;N![!R# M#_TNIQQM\:>==;O_&N\/4$L#!!0 ( #Q@4$@2ZE_8/@$ &D# 1 M9&]C4')O<',O8V]R92YX;6S-DTU/PS ,AO\*ZKU+TZ$A15T/@#@Q"8DA$+>0 M>%M8\Z'$4]=_3Y9U+0,NNW&K:[^/7\=))1P3UL.3MPX\*@A7>]V8P(2;9QM$ MQP@)8@.:ATFL,#&YLEYSC*%?$\?%EJ^!E$4Q(QJ02XZ<'("Y&XA974G!A >. MUO=X*0:\V_DFP:0@T( &@X'0"259_6*VQK:F(J.^KJ+CA@=<6*E6"N1M-Y;] M3L7."%Z'HQSDT#[]_=-#RI"LK]P'-52U;3MIIZDN#DS)V^+Q.9U-KDQ ;@1$ M55 ,.P?S[-3Y=7IWOWS(ZK*@L[PH[7&!U>3ES9VOKNF/H1G;VJ^@M02P,$% @ /&!02)E&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T M$W-I=MNTF83M3A^%$5B-;'EDD81_OTV23;J;/ 0LZ?O.14?GZ#AY M\^XN8NB&B)3R> +]O6N[!3+UES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4? M,_@5RU2-9:,!$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA M5,+$P&IG/U9KQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M M&N#C\7@XMLO2BW A(5M>5 TR 6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T M1G*=D 4. #?$T4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7K;YH]5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J M-2S%UGB5P/&MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZKR2. MFJW"$2M"/F(9-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$. M$9)>-T(^8LZ+D!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]07 M2N0/)J<_Z3(T!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL! M_]':-\*K^(+ .7\N?<^E[[GT/:'2MSAD M6R4)RU3393>*$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.W MF)&Y"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>( M\J(A[J&&F,_#0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R M4E5@,5O& RN0HGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K> M9;'!51W/55ORL+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4X MOT4SMA*7&+SCYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5 MYYN MTB42%(JP# 4A%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+ MA=OB5,V[&KXF8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.'YA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> , M?-2K6J5D*Q$_2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H: M,]6+K#F-"F]!U4#E/]O4#6CV#30,9FV-J/D3@H\W/[O#;#"Q([A[8N_ M 5!+ P04 " \8%!('5 \*S," #G" #0 'AL+W-T>6QEK=:^8^7-\?XA3VXA,!Q?,YC&(17T#N?=.V?YM5G1]2AH?;Z&I*H M$'Q9B@&2J'D">T2U?V#<,T&%!$KW2FNP"$<,.X];1$DJB0$+Q @].'AC -O> MWH\1+J3-[3(H%!Q10SE$](:FS3"E]^8R/Q0+[JX SL<\8Q\"HV(P=2-Z<[H&MJG> MG,UQSVBO7T0+NF+DU]&HKNGA$R4E9]AI==!6]+OGZ(,3]$F$!E90"4F>M+^Y M!YD&L(1@CZ4BV1SY(5&]PYWJ+[#7%:<4OK3DOZGISW=M4J-OX+]NSW]-/G\V M]E\(C_2<\2CN6I9BN;6C^=>%O?_P6I695\^KE1;^IC2O'W&S.;J8HB,*TI90 M1?B@ 9GWWIW131<3;IJ@FC/OIN%I3Q5*]5?'(HLFRW&!6JJ^D;U0]C"&D_W% MR _"T6LW4L1PLK_BG+3LVBJ8/FV2GU!+ P04 " \8%!(S%%7K[4" B M!P #P 'AL+W=OUC!A*)7EW:X%I(_P9_ACCX)O+0;Z#<)2)UYYPE81[5#"*J?"(UN^2^TR"?U*IR__U1E1=G$.+R4AE M)%8.*&2J]LV#TO@8X/ TJR\V0P$O9IJ%^U)AT#(9)?%]/$O(?$+FB_AAE$SG MLR4"=!&@>PRX'MV-9N.8+&_C.$&R4R0[_4%&GA?,0#8YKVOVC# ]A.G]$/YX MM+PED[OY$PZ_CP#]%D!5%,R\$;TF2[%1 OX?YLN:IKJ"LB+0 ($&QZ"I>H4, MP"#<(M$9$IT=BV)F%+C/DI(;$$$1D/8<:<^/M6-=%,)Y$UC"P 5C,":PN$J; M(5P@S,4Q9B(4 XG:8,]TL&DZ;CL.W"%M^A M>I,3^/4DM[^P'OLO;#%@0W_#'1.R"<#."UNL=]R[3PY)^ ZCL ?#%A-^VTIR M@E'8A6&+#3_;V0C&54PVDL.^#%N,B1O\/0F[-#S_F&!?0POFME \\R/=UK? M_YWZ.0^/?9][_1 LZM?W,/LCZ@O"!'>9]MT_.A70O0' 'A1D1;S%]J33OZY4M9B(9OL M!GC/""ZUJ6T "H($M+CN_#S3?6\LS^A=-'5'WIC'[VV+V;\3:>AP]*$_=;S7 MMTJH#I!G8/:5=4LZ7M/.8^1Z]%_AX0PC)=&*WS49N/7MJ<%?*/U0C9_ET0_4 M&$A#"J%"8/EZD#-I&A5)DO^.09],9;2_I^C?]73E\"^8DS-M_M2EJ.1H ]\K MR17?&_%.AQ]DG$.L A:TX?KI%7/F CERA4>UYW,+)><&9>]CSS( MP$.%&15(*TZV LX*(&// .0"C'9DV9$+<+85H1L0N@"AF4%HV2.W/7+9(V./ M+'N\')]1G&Q%X@;$&X#8LJ=.@*W8N0')!B"Q['LGP%; P$U(-PBI[8=+1&(0 M1M*9;0[@RCKM-B [&_+EI,0&LI"L')7]!F)O^R/G4BTDL1NA;H=5AOKYC) X M%VO4F-7:I5&ZMBG0F;H3:9&9[J.UU*P<+NC,WXEBIR=TGZ^%!JW-Q9G$$\7. M8@3=E(4&K5"V MN;R](GU%/^5YUN,;^879K>ZX=Z%"7O3Z5KY2*H@<2? B3WTE"_#<:,A5J,]4 MI8,I2:8A:#]5V+G,Y_\!4$L#!!0 ( #Q@4$@#V9?G! 0 +81 8 M>&PO=V]R:W-H965T&ULC9A+_"N5[@MZ/E..J,;"U M>]BJJ3GLG(DMV]3P\ *.9[_](AZ.Y#3$%P/RK]7];PFIT?I:U;^:DS%M\+O( MR^9U=6K;\TL8-KN3*=+FN3J;LOOG4-5%VG:/]3%LSK5)][U1D8<$(1$6:5:N M-NN^[7N]65>7-L]*\[T.FDM1I/5_6Y-7U]<57DT-/[+CJ;4-X68=WNSV66'* M)JO*H#:'U]4W_))@99&>^"7= M1";/;4^=YW_'3C]\6D/W?NK]CUYN%_Y;VIBHRG]F^_;418M6P=X_JBN M?YI1 [<=[JJ\Z7^#W:5IJV(R605%^GNX9F5_O0[_<#6:P09D-" W@YL?V(". M!O3#@"T:L-& />J!CP;\SD,X:.\S%Z=MNEG7U36HA^$^IW96X1?>CAB0+G=-U_J^(6P=OMM^1H3TR-9#.(3$+H)O1-CYOP5!H"!&#\3U #F(/$* M,7S923+3B1%4 MQ1Y%M13@2I'X/A%#>QSF I" MX-4^N7/-B79J'%_E4FV W>* @EO=%KN;-!AW]#42>\@3)E0CT%TRTY>O::D: MP&XY<+].C 4/9E^-W%CQ^" PNED5NJ"+!;$M"[2:)& ME>[>_(2>$8A%GS ,8?$]ACF$)0M.?75+]0!V"P*&8'7B,77WV(PZ\9BZ>:>^ MNJ5J +OE (/+ >SNRPH1B1GXOD2/@O&C8+((^BK!FF!2Z18%#-R'MB/S@,H' MP?A1,%D$!Y6A\U%:F/K8'PDB1\_=&W8RZ?[VD)M#:V]E M=U\/QPK#0UN=IU.2VU'-YG]02P,$% @ /&!02*DR%EX# ML8JBO2@0Y**]UMKTVHADN9)VG;Y]J8.=H3%D]L8Z_4/^)(]/SHW M9#^:^MP_KX[#<'G*\WYW=$W5?VXO[NR_'-JNJ0;_V+WF_:5SU7X*:NH<&%-Y M4YW.J\UZ>O>UVZS;MZ$^G=W7+NO?FJ;J_MNZNKT^K_CJ]N+;Z?4XC"_RS3J_ MQ^U/C3OWI_:<=>[PO/K"GTJPHV12_'URUQ[=9Z/YE[;]/C[\N7]>L=&#J]UN M&(NH_.7=E:ZNQY)\S?\NA?ZLK=LE>W= MH7JKAV_M]0^WM$&.!>[:NI]^L]U;/[3-+625-=6/^7HZ3]?K_,6P)8P.@"4 M[@&\2 :()4 \!.2SLZE=OU5#M5EW[37KYL&X5..8\R?A>VZ7]=/+;NXNW[+> MOWW?%&*=OX_E+!*8)%LL 4I1!H44=TGNZ[^; ,J$F$T CI=TO*#BBSE>X'@5 M6M1S(V;)>9)P)4RA@-*56 =,6(O*"_P4"3\%]J/#>M3LIT#U" W 05&Z,M!) M72@=Z5^9\".Q'T/ZD:@>RZP!-([83Z#C7LDY[48(,U62 MC=\NFF62%5PK_DC/FZ=0:8W'8F2N<1+4"^@Y)G5L?O 46CEFJZ39RHM@]+5@ MADR3,A0*9;2-M2J%5X[Y*FF^<@Q.8)IQ30K+4,BEE2K63RG$ HTG-*4,4WHA,3L;69@SJH(@R#%1@HQ4+ +%0T"P&"S!M3BI'K;_F@E(52L=R#U*85, L5R=TMX.WH M)[]D2C TH4.ELEI9%=N)I_@*F*^*YBM@;'[R:ZMAVM T^X4T])5B+&#&*IJQ M( /N^YV189'>"FFLK. Q\D.*LH IJ^B=+ 1;V=0J^Z!,K;*0(BU@TD9SD^3B M[4!F/D*CU+81[ =H9']-(UHR^\C14?=2O;J_JN[U=.ZSEW;PI^;IB'MHV\'Y M@MAG/^)'5^WO#[4[#..M]O?=?+Z?'X;V9_4$L#!!0 ( #Q@ M4$AMD;=6D@( -T* 8 >&PO=V]R:W-H965T&ULC9;= MCML@$(5?Q?(#Q. _G"BQU+BJVHM*J[UHKTE"$FMMDP))MF]?,(X+NYAX+]: MSS#?8'(TZSME;_Q,B C>VZ;CF_ LQ&4517Q_)BWF"WHAG7QSI*S%0D[9*>(7 M1O"A#VJ;* 8@CUI<=V&Y[M=>6+FF5]'4'7EA ;^V+69_MZ2A]TT(P\?":WTZ M"[40E>MHC#O4+>EX3;N D>,F_ )7%\H?5.3'X=-"!0# M:J"VP?-Q(19I&[20S_QDV_9]3!9KCQ^[?^G(E_@YS4M'F=WT09TD+PN! MCOC:B%=Z_TZ&&C*UX9XVO/\?[*] N(Q M *;>@&0(2#X$1)JLK^LK%KA<,WH/F/X8%ZR^.5PE\N3V >\7F3XN61F7J[<2 MP75T4_L,DKB7;$U)[%)4IB)-1TDD\X\0L0LBU1"Q"?$A!=(06M+U$HB _'/) M*H_,HDD\-(E)D]AI"DV3&&G D"7J)H4622IAR0U25([2:Y)4K/@#'P^&*VK M?#J+)_/P9"9/YN3)S**=)&Z%Q9![&'*3(7%&K[Q"BT@9 M]B22>CDR%<[BMX.F&S0Q@BER,GF%-I/3=Q],IF<6T,T$C51Q"@!*G,+**[29 M?#8,+1^>^/;09YUPAG?"6>8YK;)I?/8)9_@G-(TQGOYQ^'0VD<] X0P'A<\M M=$)B<_A,%,YP4?C<1BTA5*H?=,V/+-A5 #N!Q]M]'?'E:V8:]&!!OJ]]&TF-I M>[?-C_9B3!?\JLJZ?=EFM/>7#6SFAN_%^=+U M#>%N&S[BCD5EZK:P=="8T\OF(SQG*'O)H/B[,/>6W >]^5=K?_0/?QU?-J+W M8$ISZ/HNR^V[O7\Q40]QW>+!E._P&AUO;V6H.V015_FN\%O5PO8]OE)C"^ "< M O 1\,C#!\@I0+X'1$.EH[.AKD]YE^^VC;T'S3@8U[P?O;3N$V?.O[F20X2/94 @]%Z#I_9$ NPQ2.))Q-D'F*A,\@N0QRK$'2 M&B0?'W'QT1@?D7BI?(OI6,0HJ0?)$Z!4$I$39IXPC5%CS!N*5PJ*:4$1'Y^L M%)30^-CWF8P%)<1G(D%%$2?+/%F2 J:\FW3%34K=)*R;E*2!5"G6"Q6ABA<& M6JTX4=1)RCI17I)$L$X\4:K(G/&LZ!4KFEIAZ]WK/^:<%JSEC.H$[Z3GV>)L MZU^^>]$+/; 0F8H!B@C-?K/]I)G+B84$8,OQA!'$(!96$+#4F2U1J&@VTW[2 MC)DTNOG-&Z*R)P0IXP4, DNIV1'%5*1Y1Y*FTFG*+M[,EX&(< $2L(8]H-R+ M%T;-XYF;@\@NX,S7022$7K+$@F^V1,D7\RMTTDQ,(E1VLX!(9X M0I .QPDN>%KC+%+.:GX[AQ2@D$@5)?QVSA?&4OUWWQ&2#7=EFO-P$&F#@[W5 M7;_%):V/P\Y'[#?L?[3OW2%H/+*\=[/;7O.S^9HWYZ)N@U?;N>/ L'<_6=L9 MYU!\<)B[N&/:XZ$TIZZ_3=U],QY&PO=V]R:W-H965T&UL;5/; M;J,P$/T5RQ]0@Y.TVX@@-:VJ]F&EJ@^[SPX,8-47:IO0_?OUA5!2\8)GAG/. MG/&E&+7YL!V 0U]2*'O G7/]GA!;=2"9O=$]*/^GT48RYU/3$ML;8'4D24%H MEMT2R;C"91%K;Z8L]. $5_!FD!VD9.;?$80>#SC'E\([;SL7"J0LR,RKN01E MN5;(0'/ #_G^N V("/C#8;2+& 7O)ZT_0O):'W 6+(" R@4%YIGR!:81=$*RTL/&+ MJL$Z+2\4C"3[2BM7<1W3G]W=1%LGT(E 9\*O+!I/C:+-)^9861@](I.VMF?A M!/,]]1M1(1N+)DWOC5I?/9?W]P4Y!YT)0B/DN(3D,X)X\;D#7>LPT>F"3M?I MFS7Z)AG<++MGV;K =DU@FP2V5P+Y]8@)<[S&_'1)%ELJP;3QYEA4Z4'%>[JH MSI?S@<8C^8:71<]:^,U,RY5%)^W\P<93:+1VX$UD-SN,.O]\YD1 XT)XYV.3 M;E1*G.XO[V-^I.5_4$L#!!0 ( #Q@4$C01$ICI $ + # 8 >&PO M=V]R:W-H965T&UL;5/;CILP$/T5RQ^P)H9LVX@@;;9:M0^5 M5OO0/CLP@+6^4-N$[=_7%T+(BA<\,YQSYHPOY:3-N^T!'/J00MDC[IT;#H38 MN@?)[(,>0/D_K3:2.9^:CMC! &LB20I"L^R12,85KLI8>S55J4[,91@VT;!3N34\_8!YA'P1K+6S\HGJT3LLK!2/)/M+*55RG]".5:71$S)I:P<63G!WH'XC:F1CT:3IO5'KJY?JVZXD MEZ S0VB$G-:0&X)X\:4#W>HPT^F*3K?I^18]3P;S=?O]\ED1 ZT+XQ<&PO=V]R:W-H965T&UL M;5/;CILP$/T5RQ^P)D[VTH@@;;:JVH=*JWUHGQT8P%J;H;8)V[^O+X2%BA<\ M,YQSYHPO^8CFW;8 CGQHU=D3;9WKCXS9L@4M[!WVT/D_-1HMG$]-PVQO0%21 MI!7C6?; M) =+?)8>S5%CH-3LH-70^R@M3!_SZ!P/-$=O17>9-.Z4&!%SF9> M)35T5F)'#-0G^KP[G@\!$0&_)(QV$9/@_8+X'I(?U8EFP0(H*%U0$'ZYP@LH M%81\XS^3YF?+0%S&-_5O<5KO_B(LO*#Z+2O7>K,9)1748E#N#&D6;7X4316YP)"9M M;2_"">Z.W&]$26PLFC2]-VI]]5KLLH><78/0A.$1:C!-O#J6E#AT M\:(NJO/M?(Z'R#[A1=Z+!GX*T\C.D@LZ?[+Q&&I$!]Y$=G=/2>O?SYPHJ%T( M'WULTI5*B&,"*+]0V2_KW]84E$-$7/#.<<^:,+^6DS:OM 1QZDT+9,^Z= M&TZ$V+H'R>R#'D#Y/ZTVDCF?FH[8P0!K(DD*0K/L$Y&,*UR5L?9LJE*/3G % MSP;944IF_EY Z.F,+]J_1J2'\T99\$""*A=4&!^N<$3"!&$?.,_L^9[RT!OL,\PC$(UEK8^$7U:)V6=PI&DKVEE:NX3NG/ ML9AI^P0Z$^A"^))%XZE1M/F5.5:51D_(I*T=6#C!_$3]1M3(QJ))TWNCUE=O M59YG);D%H1E#(^:RP2P(XM67%G2OQ4RG*SK=IQ_VZ(?D\+!Q^)_^Q9Y D02* MC0#=CI@PERWF\*$)6>VI!-/%JV-1K4<5+^JJNMS.1QK/Y!U>E0/KX"1/1PQZOW[61(!K0OA9Q^;=*52XO1P?R#+*ZW^ 5!+ P04 M " \8%!(Z^[@ :0! "Q P &0 'AL+W=OZ !*WX0VPS)W\-'(#$)0_7D"KL9CDB77PBMK.^L+ MN"SPS*N9 &F8DDA#>]GI=Y\\J<^)JFW !PJZQ6H M6R[P )Q[(=?X?=+\;NF)R_BJ_A2F=>[/U,"#XO]9;3MG-DU0#0T=N'U5XS-, M(^R]8*6X"5]4#<8J<:4D2-"/N#(9UC'^(;\GVC:!3 0R$WZEP7AL%&P^4DO+ M0JL1Z;BU/?4GF!V(VX@*F5#4<7IGU+CJIY6#O?; OF60!X%\I7 [7K$B#FM,7<_FN#%G@K0;;@Z M!E5JD.&B+JKS[;PGX4R^X671TQ;^4MTR:=!967>RX1@:I2PX$^G-/D&=>S]S MPJ&Q/KQSL8Y7*B96]=<',K_2\@M02P,$% @ /&!02%OG#&VD 0 L0, M !D !X;"]W;W)K&UL;5/+;J0P$/P5RQ\0@V>2 MS8X8I$Q64?:P4I1#]NR!!JSX06PS9/\^?@!A5ERPW5155[O;Q:C-N^T '/J4 M0MDC[ISK#X38J@/)[(WN0?D_C3:2.7\T+;&] 59'DA2$9MD=D8PK7!8Q]F+* M0@].< 4O!ME!2F;^G4#H\8AS/ =>>=NY$"!E019>S24HR[5"!IHC?L@/IWU M1, ;A]&N]BAX/VO]'@Z_ZR/.@@404+F@P/QR@4<0(@CYQ!^3YG?*0%SO9_6G M6*UW?V86'K7XRVO7>;,91C4T;!#N58_/,)5P&P0K+6S\HFJP3LN9@I%DGVGE M*JYC^K.;:=L$.A'H0KC/HO&4*-K\Q1PK"Z-'9-+5]BQT,#]0?Q$5LC%H4O7> MJ/712YGG]P6Y!*$)0R/F=(59$,2K+RGH5HJ)3E=TNDW?;=%WR>'NRN'/;8'] MEL ^">S7 C2[+C%A3M>8_XLDJSN58-HX.A95>E!Q4%?193H?:.S)-[PL>M;" M'V9:KBPZ:^<[&]O0:.W F\AN;C'J_/M9#@(:%[8__-ZDD4H'I_OY@2ROM/P" M4$L#!!0 ( #Q@4$B%?+Y%P $ 'L$ 9 >&PO=V]R:W-H965TYAI:J']NS %9M3&T3 MNF^__B$4*JN7V!Z^OR$>\E&J=]T"&/0I>*=/26M,?\18ERT(JN]D#YU]4DLE MJ+%'U6#=*Z"5)PF.29IF6%#6)47N:\^JR.5@..O@62$]"$'5OS-P.9Z237(K MO+"F-:Z BQS/O(H)Z#23'5)0GY*'S?&<.80'O#(8]6*/7/:+E._N\*DO5,.CY&^L,JT-FR:H@IH. MW+S(\3=,+>R=8"FY]K^H'+21XD9)D*"?866=7\?P)#M,M#B!3 0R$PZI#QZ, M?,PG:FB1*SDB%5YM3]T_N#D2^R)*I'U1A>YM4&VKUV)#2(ZO3FC"$(\YKS S M EOUV8+$+"8Z6=!)G+Z-T;F^ ]02P,$% @ /&!02(IZB&6E 0 L0, !D !X;"]W;W)K M&UL;5/;;MLP#/T5P1]0.7*R2^ 8:#H,V\. H@_; MLV+3ME!)]"0Y[OY^NCBN4_C%(NES#DF1*B_<<*34UCTH M;A]P .W_M&@4=]XU';6# =Y$DI*4Y?DGJKC0657&V+.I2AR=%!J>#;&C4MS\ M.X/$Z93MLEO@172]"P%:E73A-4*!M@(U,=">LL?=\;P/B CX+6"R*YN$VB^( MK\'YV9RR/)0 $FH7%+@_KO $4@8AG_COK/F>,A#7]DW]>^S65W_A%IY0_A&- MZWVQ>48::/DHW0M./V!NX1 $:Y0V?DD]6H?J1LF(XF_I%#J>4_ISR&?:-H'- M!+80OD0"38EBF=^XXU5I<"(F7>W PP1W1^8OHB8V!DWJWA=J??1:[=C7DEZ# MT(QA$7.^PRP(ZM67%&PKQ4QG*SK;IA=;]")56*RSY\6VP'Y+8)\$]FN!(K]O M,6'.]YB/3=+5G2HP75P=2VH<=5S45739SD<69_(.K\J!=_"+FTYH2R[H_&3C M&%I$![Z(_.&0D=Z_G\61T+I@?O:V22N5'(?#[8$LK[3Z#U!+ P04 " \ M8%!(&S$*?Q " #[!0 &0 'AL+W=O@ F:V$[IO/U\(A-DFB]C7OF'H0 ^_-FZ.0'=-F*$^)&B1G M!V?JV@2F*4DZUO1Q6;BY5UD6XJS;IN>O,E+GKF/RWQ-OQ;B-07R=>&M.M;83 M25DDL^_0=+Q7C>@CR8_;^#O85-0JG.!WPT>UZ$>6?2?$NQW\/&SCU"+PEN^U M36"FN?"*MZT-,H7_3IF?):UQV;^FO[C5&OH=4[P2[9_FH&L#F\;1@1_9N=5O M8OS!IR5D-G O6N6>T?ZLM.BNECCJV(=OF]ZUHW^#X60+&^!D@+,!X+L&-!G0 MC2'Q9&Y=STRSLI!BC*3_%@.SGQQLD-FY?:39H_0AS\UZJ5#A@E #= R>*<#NS$?S%Y:GH5[80V1]Z=SZ,0 MFINT],%L>6UNXGG0\J.V76KZTE].?J#%<+UJY_N^_ ]02P,$% @ /&!0 M2$F+'%_R 0 >P4 !D !X;"]W;W)K&ULC53; MCILP$/T5BP]8&< M,V=\F:3GXDU6 J],]K(G5.EB8V]B#3AG:)U R\"R8XQ(O[N@?)^YP7>&'BMSY4R 9PF>.(5 M-8-&UKQ! LJ=]QQLC[%!6,"O&GHYFR/C_<3YFUG\*':>;RP A5P9!:*'"V1 MJ1'2B?\,FM>4ACB?C^K?;+7:_8E(R#C]71>JTF9]#Q50DHZJ5]Y_AZ&$E1', M.97VB_).*LY&BH<8>7=CW=BQ=W_6(VV9$ Z$<"($]PG10(BNA/@N(1X(\:,9 M5@-A]2$#=K7;G3L01=)$\!X)=]HM,91(VJ!P!Z+W3NKH)0VBKPF^ M&*$!$UK,?HX)5TN0PXW,A,#:P.0B7'(Q9 CG&9829#>(]:*'_XH$HB=0'PC$-R:7+N]<)C&8K[XX2:(-TNX[$'?]$.H="><%A1*9:8;/1>N.;B%XNW8ZJ9^F_X# M4$L#!!0 ( #Q@4$CDY(H/E0$ 'T# 9 >&PO=V]R:W-H965TQRC!<8% M$F__OEP<-ZZLOIB9X9PS9S!4(]HWUP-X\JZ5<0?:>S_L&7--#UJX!QS A)T. MK18^I/;,W&!!M(FD%>-%\QP.J*S;Q6:C!.HB$6N@/]M-D?RXA(@!\21G<7D^C]A/@6DV_M@1;1 M BAH?%008;G",R@5A4+C7Y/FWY:1>!_?U+^D:8/[DW#PC.JG;'T?S!:4M-") MB_*O.'Z%:81=%&Q0N?0ES<5YU#<*)5J\YU6:M(YYI_PPT=8)?"+PF<"S\=PH MV?PLO*@KBR.Q^6@'$?_@9L_#033$I:+-TP>C+E2O]:;D%;M&H0G#$^:XQ&QG M# OZ-A1TH>W,"<*.A_#IQ#;?#UR MXG&X7?;YQ=5_ %!+ P04 " \8%!(2U9%T? ! )!@ &0 'AL+W=O M]Z,S. M7K371#$Z"V*!Q.W;EX.QLD/-18#?[\2O4$Z,OXL.8QE\4#*(8]A).1X $'6' M*1(O;,2#>M(R3I%42WX#8N08-89$"4BB: P*DWME5)_3IBPZ1C&X;/PUM\ZJ0N@*L'":WJ*!]&S(>"X/89?XL.ET @#^-GC2:SF M@Q=+[XWQS#2$3#!M=0*2 T/?,:$:"%E_'O6_&>IB>OY4_VKV:U*?T4" MGQGYU3>R4V&C,&APB^Y$OK'I&YZWD&G!FA%A_H/Z+B2C3TH84/1AQWXPXV2? MY-%,\Q.2F9 LA&*;D,Z$="'$<), 9P+\1 !V*Z81%R1157(V!=R^O!'I;R0^ M0-7J.A"FR&U_52N$JCZJ&.8E>&BA&9,8S,G%%#[,>8U)?(B+J[)?,$"E7*(F MOJBIC9JL!;+(+Y#Z!* 52!V!V$V9V[U:S& P661^/MQE"^<$@AN!H!,H\0:" M*Z-T_W^?;,,GP^OQ.P.H0CNN$?B-_Z0017)M5Y-H>O94QBI12]J,YWZEY> M%@2W4D]S->?VJK(+R<;GQ;O<_M5?4$L#!!0 ( #Q@4$A,&R=C80( #X( M 9 >&PO=V]R:W-H965T>SJ5NZ=DO&NI7GT:)$#:1/N$,M?W+"I(&,#\G9HQU!\"B3FMH#OI]X#:Q: M-\]D[(WD&;ZPNFK1&W'HI6D@^;M!->[7;N#> N_5N60BX.69-^8=JP:UM,*M M0]!I[3X'J_U2**3@5X5ZJMT[@OV \8<8_#BN75\@H!H53#A ?KFB+:IK8<0+ M_QD\[R5%HGY__JR,K.:SO.D=T@I>:O>/^%0U3B(5A@6LJ M?YWB0AEN;BFNT\!/=:U:>>W5DS08TNP)8$@ 8\)8QYX0#@GA/2&:38B&A.C1 M"O&0$'^IX*FYR\[M((-Y1G#O$/6V.R@^JF 5\W=3.%0&B7HAO'>41Z]YD 29 M=Q5&@P9(S4;7@-@FV1DVH\+C ",%L%$,%8!>P59@:R@2*\.W)OL)$P,SM&&& MJEFAT2Q@-XAL!I$RB R#T(1,52^4IE600>3[ODVVTV412'69@1//X,0&3F36 M211._ V.DNWB!W&2&9S$P(FM.(E6)TC2=*(]6T/GIXLI[@?]]G-^Q@33F0FF MQ@03ZP13K9 =65<$()HD6?<] [*Y?XIM@M0TL\1T_*M7) M=K?/LPZ>T4](SE5+G0-F?$^7&_ )8X8XMO_$ET_)#_-Q4*,3$[&UL[5U;;QO)E7[._HK"8'8C 2V:NEBR[(D!FI)FE,B2 M(\DQ%H,\%+N+9,WTA=/5+9GSE%^QV 62M_TEN_\DOV3/I:JZFMVDJR%691*)F:N5)6E+PZ&P^,7F=3Y5V^_,?KM M-]7;LR*N,Y578I0GXCRO=+44ESF/H(M<[ DSEZ4RW[RHWG[S OMPOV/QOLBK MN8$^B4I6WYZI>" .]R-Q,-Q_N?KR]S*'ET-Z>=SIZ>@)B?C^2N=*7%8J,W]> MV^%^N5"K+_>'>W]_Z5NX'^9"FUBFXE^5+,4%/.QP=[6EG;>W[1\/5I_8;;Q5,VVJ4L(PUS+K M$#NZNKH\/Q/?G8^N[K\;CV[/Q8?;F[./X_L[<7D]7C/F&(@J@:!+V/7/X@]J MN=IN7)?EZA+7L6MO;WB\=SA<,]6%3E4IQM!O5I2=>>XRF>+[6[4HRDKG,S$N MLH7,.PWO2YG@Z[ME-BG2#A.^^W"Y;JE%EH'LW55%_&,D[D@+Q$U=F4KF.&*' MHOO1_?G[\^M[<7,A;CZK+Z]5)8Q, MNVHY+L!<%-/^E]^6A3%B4193776H5VD*BXK$3.4*=Q@6*622Z9QDJ-(/2JC/ M8%],=]PK''9:%ID U22RG;:W%1SV*T=G<=%IG;]4*]7VUWFE0)&5X);]@X3 MB5QU%G!=Y'9VV.Q+ZBQVSGF:#NN)XHD""Z/@GUP!0W@!/*NHY.?N,M]MVQ!W M)X49.@-(HV-Z(X!2-JS($I$4:2K+X&F'X#.=UI5*?EGG3TK/YMA;/@"#9LJ: M=%$TP@Q2.B'J<$1^_0N'22RE&P9Z-[H:78_/Q=UWY^?WZ_7C]W7C)SJVU-D9 M:8RJNF(TEF9.(ASC!_53K1] (_*JLR>C.$:W:D2I8@6-)JDB\4(E @M3/,H\ MQC5.Q=?[)\-H..R8J\O\ 08N2JU,KV!>>DD)YNA7C[BUJ(XE*RK0R\UM/I2H M!-4R$HL4#3^R %>_0&_22]Z9FBH8,=DHT4P>3]D["M/63Y/;JE3+B4YUI7O4 MWF_#0B[7\T?&<5FC%C0C;6;2AH9HWG6%;#$L*&"+08)5'G<;(]QZ;18R5K_[ M"O"44>6#^NJMZ-A0=!7S(DU4:7Y+;*^6G95^*!W##3;O(PN\#KU[([X>#H;[ MP)-2@/C6Z@VJ X@@_N>T3];5'(3O9Y6\$?O#Z.C@)'IU\LJ]U<8@PV0EP)^H M; ),=+",5@TZIKR.O1&OHB'TWS\ZZ=/M[0;I[&R2:/0(L"L+J9,], NQ7&C8 MI1X9J+,ZE6@]$K"T<==+72DP?Q4@6E.72V92A'3%X/;>B(/H"'AS;,5 MQ1'HI5FH&'UXKHALU@KFE(^H,T)'A;7NP M7&_;NEB/VD)]>_J"VKV_N)K>YOU+Z6VZ81WW_4JQ$:2.1W??B8NKFT\;0"HY MTBF(31OAH3E A5ECS9,?:F-M:U6@>!5@5D&Z4:8H]#:9X@,>]M]0'H,CHA*DA3U MI)K6::,MI-6(KV%A55WF_*0!"VL];*]K'<\E>!T0@SQ<,CE2&G6 3H MI ^F/G$#OB0=&F8S7]JT,9M_C@' .=0]Z05/FR6G=^2^3H!B4!- @1/%GW8% MN9PM\>!:X(@:-8&(.L^1","#"XK)G]0?EKN^YUV=91(4&!K1MT<$W$]Z,)1G%QU?$D:Z9J>MZKSY5XEX+JK/9=@XKV M!^*7+D78Q! M$>AO4L<(5 %Z#\0..$;Q][_\U>8'_OZ7O^V*.80PL)LJ!]E78/19QG#F,D$= M%H^ZF@OLJ'-@'(R&,2W9@XNBS 3FE6@-"=BQ@J0NK1.%1@!IXHY-_HI::A.# MZ4-A!W4%N2A9X63#E$4)X^@%6A8;A:?T7BTJ)A#'_9@3.^Z0"KEU@#X04,4"XCJ@2SHG,D<(CD.#I!XV5CN""&QT:QT19[2=N:XIA3M M#2!LVLC U%-[P#E 7@X&R1B4 0(:8BIU*4A(\HIX$@5[8+F7#,2-MSG0M$XK MBU/RI?BIEF6%(0!L,'+<3:"!+@U6).84A67^:N^"P@P1SB<)/[# G^H(::0 M96+$NP+^$3N@+1>CNW>D*C:"Z&W^<9' 6JC]Z.XC-$?6PA_\G+I?%P.:?F]X M&N&K6P7^"/ 5N8MQD9-5,LS-,4@2A*"E&>!0]W,-J[_["!2 *%DEVH./ANW M.5>/L"D\$J(+L#&T*5F1J!06"K;6ZICKBU)@H0@T_EGY[O P40L=5\0?3)>: M*2QC-4HD&7>:(.( O;LYIJF+>6*\-; )T1?XN]HA( MX3I@O]7GF!" WYQDXHNJP&X4!( M#O+#6SL-Q,;-T*!Z\)",,3*G!MM8(R1;[T)&]0Q4(#0J* [.3L"(7N>114 " MZ%]6YVBB@11W^D)Z0#VM:0GLRICX$[/FW '^!H\5PY O]XZ&9$7.O#/%+?D( M'KNL) @-!=T3")-0,SF/ST:4(#19@#'E>4#Q)9J&;PL^.L 1 ME_2,XG!IG*"ZC096D P^@A$$G:M0OG/>?D729NH)"G6%6T912\,*U;!"-JR( M6ZR8$2MB9@68)?#\L-_O&_))4,@;6O0"0V3R1\6B%)")6CP!E^M4%]GA-+JC MQMTI2!;=V(Z-(7S24S2G2"EZ3MP)GX #$+[.1#G'7,>F/)/H?V8*,#-#XHQ MB-_;O'#VP1F#KA4(]X(- @#7U*;2-MB#EWO#0])>?\;S7_\F+K-%S8@0Y=V_ MV?%:_^KPY=[AUYH"$4A%=$H/E/0*UT[IDQY,Q' 2'V]H MW*%@ _;ZN8]FD#A#:8&&!@)I-E?*CK^/9:; A Q,3LU3G:N]8KH'L3A82;![ M)8(=ZTP8<@.%A@SBKP1L7JX!-H$FC"C2@R'2920>K?BW72XJ &??>?F/Y$5 MP0 +R6E8_"F702#B-5'+$3II1BTALA'YMYM_$<'S[ &DHH& "$]0$\."T%&B9-$( M(BR>=!151:/5P"86=37PN4$BK?27S/U2UBLK$VC#6>3.KR3FU\4#W([)T?#76M<:XYRO?L@(T_" MC@I/'(2HT(Z+1M=.2$57WK]@=B4),L%KN.RX<=HVU24HLD^N3-V\,.BKC8C$$MF;& $6$P[D MP(P3=0^ZJ WF>VB7V[R)01X#*8>9? RV: =?;5N,50^&H)%-Y7&43@MKAXS- M7, 1HDT*M$$ETMX&31CZ%ZE.Y+K$94LO"& VK3CC&&34N*)G;08[ZCW'H\AY MY5"=9_6HA3,7+"J_PNCLUCZ374;VZ9*S?FRX$TZUD*.98R8+FM4E^@LV+D:% M"Q^L.\8 =XU^87T^VS<408SX]"3V 9H9?W+2[ F,?' MT>G+@UWZ?'( GX]W@:33:'CZ*CJ T?#S_BF0"HB@4P@G2S08P0'HVA8?H 65 MR&W8FK[&3]Z80[(H*V0)KJQ2W1?X'Y_X%6RL'E>+F/*:-A9KYNPA*Q7^4-+" M'<"VRB"2NG1.RSDY5YVU#0&FSIP_W8J6%AU'2<=6\5"QC1G\6&5&Z(UBB^XJ,=\+&ESS=ILPD>:Z#;0>3@A'4%OP'& MR!/32H+P9PR-F_Y8^5=C>(/)KYP*QPA% *$5'<=R7TS,L%QP"/1B9O+J#:@;F'/ -L+F$O3G D-DMO M[)8%D6N(Q^CDJ\G-/VEOII1[ E 5T1$V3/2@U6.$J2A-A;@3Y4).RQO*?$K.2%,^4.B 178Y8F7+9'H94"/7 MT!,1CK4 $M=!,!N#V)F5'[=K/1[8T_QYW3..D7^ MK!"V(*$Q]CP*L-?!L+U#IQ(QVJ#TY;117GOF!_NH76RU3/'+?PG+A M7P:3GVH/TY,Q/L03%@C>L(8%8HJ2X][ O+EUL]-DI^>++6S:96'7@RH*;AL% MYN#4)1=")CIGUK/A@*J*],&*)SJ"UF[ZGIU]%@N ,K7D0SK0_[JJJ7P&2_P, M @@,B(RJ*L[>@D@ I&T4A;7"K:@[+]J"1)L,5JK:AG@_.*WII^Q1!LO"BA\* MZY$(5"=+CCVQECF+N#?^K:D.PK2?8R;E:SA-TCV:PP80GS,PK6WR5O4R(A)@ MD $$E(1/\(S'8CQ>5P/$5&#R6.S^EV2.,X^KMJ*]>G^@TIQG29O$[UMD<,(8 M9&\XJR:*O(6#HR ILRCX:#WRI45 67/;2;@4"M5"0HB:+=*"N.YK7#I 5-%I M"V7N"DJ?-WUBUX>2BTA3/ ?+"L!,Q;6M]6+9U+J!],(Z,$WT"/\!P&K.2'F)8/S(F4Y;YL0M#)$S$M PLKU, MV"3H]5"D@)RYQIP54'@"/OL5'M_0(GS3D>T['34TO:5L,DH*< MQ3F2FL.*4D"$Z>.58&8L1X%=+)KA=O1NQPT\EIA"!:G!@B,'\6!9/!UB9%K%/BZ[T?9C&,2!N5JR MS[DJ)!_@WF%U)*8V1XUMY5RP/[?8)^2'-7$D:.=H"Q84H[^3^8_B7V2V>"/N M2ZRS\?6K?(+JQR1D$WJ]1CL=?<4$]Y@ E$&:J.((=OR!(AT>#VRZ/:<>NR"1 M%]G83'L0;&QA1UG:K>=0D@LC@%GU JGX6KST5Y3(Y*V03>[0G4\7P5&.*S"# M;;-*SV['IHE=YGVE_3%6&_L,BJV[L_4X]FPETY65:O (N :TJ;;061J"_WHH*B[NF.ZF&$W"@-(JKFUH7R8>6M<]3IB M,*%.J,'E]D?) U_M^7+?3(+/;0.F6[\8V^FZP,K.KA*OLFS7F@?&-BL(FV-- MD(T- HX;B,DB1[XE4MK"%ZP&P026*%$ O(JMHR2PH\UP'+7Q90+ %]:)/G&BJD>,F]8>QWB8*6>PU!FRQ%:- M UOWCJZPWZ5-5+#(9LC1<.$JI;D0*U):VQ#_1J"68U.5-Z=[,>=/<9T/0PG&L M:VBOJ1*492#KJ*$R"6GO33!*!>R08GX5A@P.2"E[J\J9+2^B:XDNP\L<!;1AD$45?SI/R"$UW*/" <>D*#A)7_5 4;^R-#@:W9+5 M?*_V+O3B CEEXE)/4*,F,/AV@F:794M(875@)B2$&DW!:"/.P<$YJK@[GZZ6 M"V7II.]R["!B)"SRDLO&@D3>Y$+LHQBE%K:@C'T4%Y_B363* MC)5D'C"9%XA9>,V#RR^IZHM@KUUNXTY2!$V)_;H3E S\CHH]MW02";_A1 EL M+$BW2NBDH6@% F]V"HIO*60L&(20@UCB!>J ,5:E_36/ M8H(XD>UKB;$Z9=>MN6V6[U'3-FME,^KKK";@&?'\ S/'I5\NR31FDX.3A3=- M2;>EF"IRFHQS:Z9VJ,GW6'*U25RYSH",+",47B#6.4#5#&UC7UPX2%XN*8 MK $,1P,+2 ^'>^C;KB[?W=QR:W3YP\'1@1CUW!=O(WY.:0?>-Q3'J-$];R%3 MNHQ83-+FR(CJ'_;(05 %):%4= C^T4J"1QK>-"S6:PHQ@[MFC=M8+;_L8UW? MK?B>@@OZ-HC[OBNKS;OM0K,U[9\X#4#@F9AP9;/AS"&X]P!GK89Y_1]T2]X-+"\"9XD@&@" M+MZJ\JM4X>GDI#G*JU2V*$HT_ U6-!XL<@U6MTR;R\+\EX_@>%S=T#\]+\,: M;TS&Y)+ GUQ";KM@?B3+_$/OAK%GD!"$,*5*^0BFOM_E)-(ZECU\L#&;,Z] M(O?M8'_KOY]9/^D0%@,Q?X!/]CG<]"#DU?\9W1\^-^D$B[K<4W]M_GZR9?M!643XEUI]O\S[?YGV^S?MK MW.;M?MW!8^O*?EGD\)GAI/G'=?H6]H0+ MG^\7/]\O?KY?_'R_^/E^\?/]XN?[Q<_WBY_O%S_?+WZ^7_Q\O_CY?O'_T?WB M3H$=9NS^Y&!$DZ6Y;.[<_N,9HRTF>;[W_,ON/5-._QZGZV;T[^(Y8,=4,<3R M]Z3=UZY_3]V>OIOAU(0@,$.F#5ML+@ UK_^?WHQN;^ENS<9?:SF3I5S[ M/>Z;2=C$#/H%DZ8Y[,Z9S"06G=\5-; I8D.\MM"Z=YO6K:)X&(CA:?_W^]-+ M5\[<6Y3=F/_-*\)7-]/5?J=;JG:_A&TNP5CW?HT]#%#U#.%OXY2%6 M*(Z:E,$MV/>(3^H2E%@\'4$IQ.?P?[ -0"J7A:T.BL6J__P/S[0Z %:T?'E4 M/IJ]HY\!0_SP)PF AW";<\O,F$53&?(]5QU-;/W@+@ZVOTKU-4VU77/%;4] M%;5/*Z?=5.'S%&O@X<;-5*RI[-GT]D>:Q([]@:7NCQ\%$908 M<5C3E*+X'[40[J=&L+X6$-H6PT1]XW3<%'M([.5^ NH"4W36Z?#.C(,?% @. MOD?KOSK?FJ2 A1U&1()^4V3M0GKZVJ[!="^,J=[^#U!+ 0(4 Q0 ( #Q@ M4$BO2Y&W?@$ /L- 3 " 0 !;0V]N=&5N=%]4>7!E M&UL4$L! A0#% @ /&!02$AU!>[% *P( L M ( !KP$ %]R96QS+RYR96QS4$L! A0#% @ /&!02#]1BQLM 0 4PP M !H ( !G0( 'AL+U]R96QS+W=O&PO=&AE;64O M=&AE;64Q+GAM;%!+ 0(4 Q0 ( #Q@4$@=4#PK,P( .<( - M " 1$. !X;"]S='EL97,N>&UL4$L! A0#% @ /&!02,Q15Z^U M @ (@< \ ( !;Q 'AL+W=O&PO=V]R:W-H965T&UL M4$L! A0#% @ /&!02*DR !X;"]W;W)K&PO=V]R:W-H965T&UL4$L! A0#% @ /&!0 M2/U@6V^D 0 L , !@ ( !L20 'AL+W=O&PO=V]R:W-H M965T&UL4$L! A0#% @ /&!02' TS6>D 0 L0, !@ M ( !0"H 'AL+W=O&UL4$L! A0#% @ /&!02%OG#&VD 0 ML0, !D ( !]2T 'AL+W=O&PO=V]R:W-H965THAEI0$ +$# 9 " <&UL4$L! A0#% @ /&!02!LQ"G\0 @ ^P4 !D M ( !HS, 'AL+W=O&PO=V]R:W-H M965T&UL4$L! M A0#% @ /&!02$M61='P 0 "08 !D ( !WSD 'AL M+W=O&PO=V]R:W-H965T XML 31 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 32 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 34 FilingSummary.xml IDEA: XBRL DOCUMENT 3.3.1.900 html 15 100 1 false 2 0 false 4 false false R1.htm 101 - Document - Document And Entity Information Sheet http://www.alliedhpi.com/role/DocumentAndEntityInformation Document And Entity Information Cover 1 false false R2.htm 102 - Statement - STATEMENT OF OPERATIONS Sheet http://www.alliedhpi.com/role/StatementOfOperations STATEMENT OF OPERATIONS Statements 2 false false R3.htm 103 - Statement - BALANCE SHEET Sheet http://www.alliedhpi.com/role/BalanceSheet BALANCE SHEET Statements 3 false false R4.htm 104 - Statement - BALANCE SHEET [Parenthetical] Sheet http://www.alliedhpi.com/role/BalanceSheetParenthetical BALANCE SHEET [Parenthetical] Statements 4 false false R5.htm 105 - Statement - STATEMENT OF CASH FLOWS Sheet http://www.alliedhpi.com/role/StatementOfCashFlows STATEMENT OF CASH FLOWS Statements 5 false false R6.htm 106 - Disclosure - Summary of Significant Accounting and Reporting Policies Sheet http://www.alliedhpi.com/role/SummaryOfSignificantAccountingAndReportingPolicies Summary of Significant Accounting and Reporting Policies Notes 6 false false R7.htm 107 - Disclosure - Inventories Sheet http://www.alliedhpi.com/role/Inventories Inventories Notes 7 false false R8.htm 108 - Disclosure - Earnings per share Sheet http://www.alliedhpi.com/role/EarningsPerShare Earnings per share Notes 8 false false R9.htm 109 - Disclosure - Commitments and Contingencies Sheet http://www.alliedhpi.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 9 false false R10.htm 110 - Disclosure - Financing Sheet http://www.alliedhpi.com/role/Financing Financing Notes 10 false false R11.htm 111 - Disclosure - Income Taxes Sheet http://www.alliedhpi.com/role/IncomeTaxes Income Taxes Notes 11 false false R12.htm 112 - Disclosure - Summary of Significant Accounting and Reporting Policies (Policies) Sheet http://www.alliedhpi.com/role/SummaryOfSignificantAccountingAndReportingPoliciesPolicies Summary of Significant Accounting and Reporting Policies (Policies) Policies http://www.alliedhpi.com/role/SummaryOfSignificantAccountingAndReportingPolicies 12 false false R13.htm 113 - Disclosure - Inventories (Tables) Sheet http://www.alliedhpi.com/role/InventoriesTables Inventories (Tables) Tables http://www.alliedhpi.com/role/Inventories 13 false false R14.htm 114 - Disclosure - Inventories (Details) Sheet http://www.alliedhpi.com/role/InventoriesDetails Inventories (Details) Details http://www.alliedhpi.com/role/InventoriesTables 14 false false R15.htm 115 - Disclosure - Earnings per share (Details Textual) Sheet http://www.alliedhpi.com/role/EarningsPerShareDetailsTextual Earnings per share (Details Textual) Details http://www.alliedhpi.com/role/EarningsPerShare 15 false false R16.htm 116 - Disclosure - Commitments and Contingencies (Details Textual) Sheet http://www.alliedhpi.com/role/CommitmentsAndContingenciesDetailsTextual Commitments and Contingencies (Details Textual) Details http://www.alliedhpi.com/role/CommitmentsAndContingencies 16 false false R17.htm 117 - Disclosure - Financing (Details Textual) Sheet http://www.alliedhpi.com/role/FinancingDetailsTextual Financing (Details Textual) Details http://www.alliedhpi.com/role/Financing 17 false false R18.htm 118 - Disclosure - Income Taxes (Details Textual) Sheet http://www.alliedhpi.com/role/IncomeTaxesDetailsTextual Income Taxes (Details Textual) Details http://www.alliedhpi.com/role/IncomeTaxes 18 false false All Reports Book All Reports ahpi-20151231.xml ahpi-20151231.xsd ahpi-20151231_cal.xml ahpi-20151231_def.xml ahpi-20151231_lab.xml ahpi-20151231_pre.xml true true ZIP 36 0001144204-16-082221-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001144204-16-082221-xbrl.zip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end